Executive TL;DR

• CXMT (ChangXin Memory Technologies) debuted on Shanghai’s STAR Market on July 27, 2026, surging approximately 466% on its first trading day to become China’s most valuable listed company with a market cap exceeding $489 billion, after raising $8.6 billion in Asia’s largest IPO of the year.

• The company is the world’s fourth-largest DRAM manufacturer with an 8% global market share in Q1 2026, up from roughly 1% in 2021, and is on track to reach 350,000 wafer starts per month by end of 2026, closing the capacity gap with Micron Technology to just 25,000 wafers.

• Q1 2026 revenue exploded 719% year-on-year to $7.51 billion, with an operating profit margin near 70%, driven by an unprecedented AI-fueled DRAM shortage that has sent contract prices surging up to 98% quarterly.

Table of Contents

• Executive TL;DR

• Introduction

• CXMT Company Profile: Key Facts Snapshot

• CXMT Investment Thesis

• CXMT Business Model Overview

• Segment-by-Segment Teardown

• Major CXMT Competitors

• Strategic Context

• Bull, Base & Bear Case Scenario Analysis

• Key Risks for CXMT

• Catalysts to Watch

• My Final Thoughts

• Official Sources & Data

Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

On July 27, 2026, a company most Western investors had never heard of became the most valuable publicly traded entity in China.

ChangXin Memory Technologies, known as CXMT, saw its shares surge 466% on debut, catapulting its market capitalization past Industrial and Commercial Bank of China to approximately 3.3 trillion yuan.

The IPO raised 57.92 billion yuan ($8.6 billion), making it Asia’s largest offering of 2026. But the headline numbers only tell part of the story.

CXMT sits at the intersection of three powerful forces: a structural global DRAM shortage driven by AI infrastructure spending, China’s accelerating push for semiconductor self-sufficiency, and a geopolitical technology rivalry that simultaneously fuels domestic demand while constraining access to advanced manufacturing equipment.

For investors seeking to understand the global memory chip market, CXMT represents a unique case study.

It’s simultaneously a beneficiary of the most powerful demand cycle in semiconductor history and a company constrained by export controls that limit its technological ceiling.

This report provides a comprehensive fundamental analysis of CXMT, examining its business model, competitive positioning, financial trajectory, the full spectrum of risks and opportunities that shape its investment profile & more.

Let’s get started.

Read more

Executive TL;DR

• SpaceX (SPCX) reports its first-ever quarterly results as a public company on Tuesday, August 4, 2026, after the closing bell.

• Wall Street expects Q2 revenue of roughly $6.81 to $6.9 billion, an adjusted loss of about $0.24 per share, and adjusted EBITDA near $2.0 billion, with the Starlink-anchored Connectivity segment carrying virtually all of the profit.

• Two days later, on August 6, the first major lockup expiration frees close to one billion insider shares, more than doubling the tradable float, with further unlocks scheduled after Q3 and Q4 earnings.

• The stock enters the print near $110 per share, about 18% below its $135 IPO price and roughly 50% below its post-IPO peak, while analyst price targets range from $62 all the way to $900.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• A First for Wall Street

• The Consensus Scoreboard: Revenue, EPS, and EBITDA

• Starlink: The Profit Engine Under the Microscope

• The Space Segment

• SpaceXAI: The $250 Billion Wildcard Inside the Numbers

• Capex, Debt, and Cash: The Funding Math Investors Must Check

• The August 6 Lockup: The Largest Overhang in Market History

• Valuation

• Key Risks

• Bull Case vs. Bear Case: A Scorecard for Tuesday Night

• Latest Analyst Price Targets

• Official Sources & Data

• My Final Thoughts

Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

Seven weeks ago, SpaceX completed the largest IPO in history, raising about $75 billion at a $1.75 trillion valuation. On Tuesday evening, the company faces its first real test as a public entity, and the stakes are unusually high.

Roughly 48 hours after the results land, the first major lockup expiration will free close to one billion insider shares for sale, more than doubling the stock’s tradable float in a single session.

Shares have already fallen from a post-IPO peak of $225.64 to the $114 area (as of now), a decline that reflects both anxiety about the unlock and growing skepticism about whether a company with a $4.7 billion quarter can justify a $1.4 trillion market capitalization.

What management says on Tuesday about Starlink’s growth rate, Starship’s readiness, AI compute spending, and full-year guidance will determine whether the stock finds a floor or keeps sliding into the unlock.

This analysis walks through every number that matters.

Read more

A quiet but consequential shift is happening at the intersection of AI and materials science.

Cambridge-based CuspAI has just closed a $450 million Series B that pushed its valuation to $2.6 billion, drawing capital from Jeff Bezos, the UK sovereign AI fund, and a coalition of chip industry heavyweights.

The round arrives at a moment when chipmakers are running into the physical limits of the materials they have relied on for decades.

CuspAI’s pitch is that AI can compress materials R&D timelines from years to months.

For investors watching the AI stack widen beyond GPUs and data centers, this deal signals where private capital is redirecting.

Recommended - Read Full Reports

Read All Reports

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

The Deal Structure and the Investors Behind It

The Series B was co-led by Kleiner Perkins and NEA, two firms with track records in enterprise infrastructure and deep tech. Bezos Expeditions joined alongside Glade Brook Capital Partners, Lux Capital, and AMD Ventures.

Strategic participation from the UK Sovereign AI Venture Fund marks one of the largest state backed AI deals in British history, positioning the UK as an infrastructure partner rather than just a talent pool.

Total funding across CuspAI’s rounds has now surpassed $580 million since its founding in March 2024 by Dr. Chad Edwards and Professor Max Welling, a pioneer of geometric deep learning.

CuspAI Series B snapshot
- Round size: $450 million
- Post money valuation: $2.6 billion
- Lead investors: Kleiner Perkins, NEA
- Strategic partners in round: AMD Ventures, UK Sovereign AI Venture Fund, Bezos Expeditions
- Founded: March 2024, Cambridge, United Kingdom
- Cumulative capital raised: over $580 million

Subscribe now

Why Chipmakers Have a Materials Problem

Modern logic and memory nodes depend on a small basket of exotic elements. Ruthenium, cobalt, tungsten, and various rare earths sit inside interconnects, barriers, and specialized layers where alternatives have been elusive.

The bottleneck is not always what a fab can etch. It’s often what nature has provided.

In an interview, CEO Chad Edwards argued that the entire semiconductor industry is fundamentally a materials science problem waiting for computational leverage.

AI driven demand is already reshaping the critical minerals market, with concentrated supply chains vulnerable to geopolitical shocks. CuspAI is one of the first venture backed answers targeting that risk directly.

Bezos himself framed that the objective is to reduce or eliminate chipmaking’s reliance on rare metals with supply chain risks, including ruthenium.

Subscribe now

Inside the AI Materials Foundry

Alongside the raise, CuspAI unveiled the AI Materials Foundry, a global network combining data, wet labs, compute capacity, and scientific expertise.

The Foundry launched with more than 45 founding partners spanning chip design, cloud, industrial manufacturing, and academic research. Confirmed participants include NVIDIA, Meta, and Hyundai Motor Group.

Rather than a pure research lab, CuspAI is building a two sided platform: generative models on one side and physical validation loops on the other, so predicted materials can be synthesized and tested in months rather than years.

AI Materials Foundry structure
- Founding members: 45 plus, including NVIDIA and Meta
- Core focus areas: semiconductors, carbon capture, advanced manufacturing
- Anchor partnership: five year deal with A*STAR in Singapore
- Near term research allocation: roughly 80 percent toward semiconductor materials

Subscribe now

The A*STAR Anchor and the Singapore Bridge

The most concrete Foundry project already in motion is a five year partnership between CuspAI and Singapore’s Agency for Science, Technology and Research.

The collaboration pairs CuspAI’s generative models with A*STAR’s autonomous synthesis and characterization facilities. The goal is experimental validation of novel materials across semiconductors, carbon capture, and water purification.

For chip investors, the Singapore link matters because A*STAR sits inside a fabrication ecosystem that includes advanced packaging, compound semiconductors, and materials characterization at scale.

Nvidia, Meta, and the Strategic Logic for Hyperscalers

Nvidia’s involvement extends beyond the compute layer. Its role inside the Foundry is to

Read more

Executive TL;DR

• Philip Morris International (PM) just posted its first ever $11+ billion quarter, with Q2 2026 net revenues of $11.2 billion and adjusted diluted EPS of $2.20, both crossing thresholds the company had never touched before, and management raised the low end of cigarette volume guidance from a 3% drop to something closer to 2–3%.

• ZYN in the U.S. slowed a lot faster than the bull thesis wanted, growing pouches only 1.8% in Q2, but PMI is doubling down with fresh SKUs (ZYN ULTRA, extra flavors) and a first-ever FDA Modified Risk Tobacco Product nod for 20 pouch variants on June 30, 2026.

• IQOS is now the biggest engine at the company, with heated-tobacco unit shipments at 41.8 billion sticks in Q2 (up 7.6%), and the FDA is still holding the ILUMA marketing order in review while U.S. rollouts in Austin and Fort Lauderdale run on older-generation hardware.

• Full-year adjusted diluted EPS guidance was trimmed to $8.26 to $8.41 from the prior $8.36 to $8.51 (a currency call, not an operational one), and PMI still targets net leverage close to 2.0x adjusted EBITDA by year-end 2026.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• Philip Morris International Company Profile: Key Facts Snapshot

• The PM Investment Thesis

• PMI Business Model Overview

• PMI Revenue Analysis

• Latest Quarterly Earnings & Guidance

• Margins, Earnings Quality & the EPS Trajectory

• Cash Flow Mechanics

• Balance Sheet Health

• PMI Segment-by-Segment Teardown

• Product-Level Deep Dive

• Major PMI Competitors

• PMI Strategic Context

• PMI Valuation Framework

• Bull, Base, and Bear Case Scenarios

• Key Risks

• Catalysts to Watch

• The ESG and Reputation Overlay

• The Emerging Markets Angle

• Comparing 2026 to 2019 (Because Context Matters)

• Analyst Price Targets

• My Final Thoughts

• Official Sources & Data

  Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

If you had told a portfolio manager in 2018 that Marlboro would eventually be the second-largest product Philip Morris International (PM) sells, they would have laughed.

And yet, that’s exactly what happened this year… the smoke-free portfolio (IQOS, ZYN, VEEV, and a growing wellness sleeve called Aspeya) has swallowed roughly 42% of net revenues, and the trajectory keeps bending upward.

Except the story is not a straight line anymore, which is the whole reason this report exists.

Q1 was ugly in the U.S. because ZYN had an inventory hangover from 2025. Q2 came back strong on the international book but the U.S. business posted a mild revenue decline. Investors are trying to figure out whether the smoke-free story has hit its awkward teenage years or whether the second half of 2026 puts it back on the college track.

There’s also the currency drag, an RBH impairment charge tied to the Canadian affiliate, and a corporate restructuring that split the company into PMI International, PMI U.S., and the Aspeya wellness unit as of January 1, 2026.

Let’s breakdown everything that matters.

Subscribe now

Philip Morris International Company Profile: Key Facts Snapshot

Philip Morris International Inc. trades on the New York Stock Exchange under the ticker PM and is headquartered in Stamford, Connecticut, with operational headquarters in Lausanne, Switzerland.

The company was carved out of Altria in 2008 and has since been rebuilt around a “smoke-free” transformation thesis.

Jacek Olczak runs the whole thing as Group CEO. Emmanuel Babeau is CFO. Frederic de Wilde was named CEO of the newly created PMI International business unit effective January 1, 2026 during the organizational restructure.

Ticker:            PM (NYSE, Euronext Paris)
Legal HQ:          Stamford, Connecticut
Operations HQ:     Lausanne, Switzerland
Group CEO:         Jacek Olczak
CFO:               Emmanuel Babeau
Fiscal Year End:   December 31
Reporting Segs:    PMI International, PMI U.S., Aspeya (effective Jan 1, 2026)
Employees (2024):  ~82,000
FY2025 Revenue:    ~$38 billion range
Dividend:          $1.47/share quarterly (as of 2026)
Dividend Streak:   17 consecutive years of increases

Some quick history matters here. PMI acquired Swedish Match in 2022 for roughly $16 billion, and that single transaction is what turned ZYN into a household name in the United States. Before that, ZYN was a Swedish-heritage niche product. Now it is the reason U.S. gas stations reorganized their counter displays.

PMI also owns the IQOS heated-tobacco ecosystem in full (they bought back the U.S. commercialization rights from Altria in 2022, and full rights kicked in on April 30, 2024). The wellness arm was rebranded Aspeya in early 2025 and now serves as the standalone consumer-health platform.

Subscribe now

The PM Investment Thesis

The Core Bet

The whole thesis, if you strip everything else away, is that PMI is turning a shrinking, cash-generative cigarette machine into a growing, still-cash-generative next-gen nicotine machine. And they are doing it faster than any of their peers.

That sentence sounds simple. Executing it is not.

The company is now aiming to have more than two-thirds of net revenues come from smoke-free by 2030. As of Q1 2026, they were sitting at 43% of net revenues, and Q2 held approximately 42%. Which… yes, that’s technically a small step back quarter over quarter, but the drop is math, not deterioration (ZYN Q1 was so weak that combustibles got a bigger denominator share by default).

Why Investors Care in 2026

The interesting bit for a U.S.-based investor is that PMI does not really compete inside the U.S. cigarette market. That’s Altria’s turf.

PMI’s cigarette business runs internationally, and they have been able to raise prices consistently even as sticks-per-year decline. Their Q2 2026 combustibles pricing variance was +10.0%, which is a huge number for a “declining” business.

Meanwhile the smoke-free portfolio is where the growth actually lives. IQOS crossed a symbolic threshold in early 2024 when the leading heated tobacco product surpassed Marlboro in net revenue for the first time. It’s just… the reality now.

Subscribe now

The Long-Duration Angle

There is also the “34 million” number. That’s how many adult smokers were using IQOS as of June 30, 2025, per PMI’s own disclosures. The internal ambition is to hit 40 million by 2030. Not a wild stretch given the current trajectory.

Smoke-Free Net Revenue Share (approx.):
2019   ~19%
2022   ~30%
2024   ~40%
Q1 2026   43%
Q2 2026   ~42%
2030 target   >66%

The delta between “where we are” and “where management wants to be” is the whole thesis in one table. If they get there, the multiple should re-rate. If they stall, it doesn’t.

But There’s Nuance

Which is fine. Nothing’s ever clean. ZYN’s U.S. slowdown is real. Rivals are showing up. The FDA has been sitting on IQOS ILUMA authorization longer than anyone expected.

So while the direction of travel is clear, the tempo has been… choppy. Investors need to be OK with that.

Subscribe now

PMI Business Model Overview: How the Money Actually Moves

The Basic Machine

PMI is a nicotine-first consumer packaged goods company. They design a product (a cigarette stick, a heated tobacco unit, a pouch, a vape pod), manufacture it at scale in factories mostly outside the U.S. (Switzerland, Italy, Poland, Kentucky for pouches, etc.), and distribute through convenience stores, tobacconists, and specialty channels globally.

Revenue is a function of volume (units sold) multiplied by price per unit. Both matter. Price has been a consistent lever for combustibles (raising prices even as volume drops). Volume is the lever for smoke-free.

Around 76% of the company’s Q2 2026 volume came from cigarettes (156.9 billion sticks). But nearly half of gross profit came from smoke-free products, which tells you everything about margin mix.

Manufacturing Footprint

PMI runs roughly 40 factories worldwide. IQOS heated-tobacco units are consumables (they buy a device once, buy the sticks forever).

Which is the same razor-and-blade model that made Gillette a giant. VEEV pods work the same way. ZYN is a straight consumable, no device needed.

Product Category      | Approx Q2'26 Volume     | Trend
----------------------|-------------------------|----------
Cigarettes            | 156.9 billion sticks    | +1.1%
Heated Tobacco Units  | 41.8 billion sticks     | +7.6%
Oral Nicotine (all)   | 5.1 billion pouches     | -1.2%
E-vapor (VEEV)        | 1.3 billion units       | +55.1%

Subscribe now

Distribution and Route to Market

Roughly 180 markets. That’s the footprint.

In some markets PMI sells directly. In others they partner with local distributors.

The U.S. business is smaller than most people assume, only around $850–900 million per quarter, but that’s growing fast and is where the ZYN + IQOS story lives for a domestic investor.

Where Cash Comes From

Cigarettes still fund the transformation. That’s the honest read.

The combustible portfolio kicks off consistent gross margin in the 65–70% range and PMI takes those dollars and reinvests them into smoke-free R&D, manufacturing capacity (ZYN plants in the U.S. cost real money), and marketing.

PMI Revenue Analysis

Read more

Executive TL;DR

• Microsoft (MSFT) closed fiscal year 2026 with a record-breaking fourth quarter, reporting $90.0 billion in revenue, up 18% year-over-year, and $40.6 billion in operating income, with diluted EPS of $4.81 on a GAAP basis.

• The Intelligent Cloud segment surged 32% to $39.3 billion, with Azure and other cloud services growing an eye-popping 43%, marking the first full year Azure crossed the $100 billion annual revenue threshold.

• Commercial remaining performance obligation (RPO) exploded to $678 billion, up 84%, and Microsoft 365 Copilot reached over 30 million paid seats, while GitHub Copilot hit 50 million users.

• Capital expenditure hit a record $35.8 billion in the quarter (lower than expectations of $36.14 billion), bringing FY26 capex to roughly $115.9 billion, with FY27 spending guided to exceed $50 billion for Q1 alone and continue climbing.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• The Headline Numbers That Rewrote the Narrative

• Segment Deep Dive: Where the Growth Actually Lives

• The Backlog Story

• Capital Expenditure

• Microsoft Cloud: The Unifying Metric

• OpenAI Partnership: A New Contractual Reality

• The Guidance: FY27 Q1 Sets a High Bar

• Security, LinkedIn, and Other Business Highlights

• Cash Returns and Balance Sheet Discipline

• Latest Analyst Price Targets

• Risks Investors Should Actually Watch

• Reading the Full-Year FY26 Scorecard

• What the Q4 Result Signals for the Broader AI Trade

• My Final Thoughts

• Official Sources & Data

  Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

Microsoft (MSFT) just delivered the quarter that answered the biggest question hanging over the entire mega-cap technology sector:

Is the tens of billions being poured into AI infrastructure actually turning into revenue?

The answer, based on the numbers released on July 29, 2026, is a resounding yes.

Azure grew 43% in the quarter, commercial RPO ballooned to $678 billion, and shares jumped roughly 8% in after-hours trading as the report reset the narrative on Redmond’s AI thesis.

For investors who watched MSFT trade near 52-week lows in late June amid capex anxiety, this quarter changes the story.

This analysis report is a segment-by segment breakdown of how the numbers matter to your investment thesis and where the risks still live.

Read more

Executive TL;DR

• Abbott (ABT) closed the $21 billion Exact Sciences deal on March 23, 2026, reshaping the Diagnostics segment into a cancer-screening powerhouse and adding Cologuard to the portfolio.

• Q2 2026 revenue landed at $12.59 billion, up 13% reported, with adjusted EPS of $1.31 beating estimates. Management raised the 2026 adjusted EPS range to $5.45 to $5.60.

• Medical Devices grew 9% to about $5.85 billion in Q2, driven by CGM, Structural Heart, and Electrophysiology. Nutrition slipped 3.6% comparable, the current soft spot to watch.

• Balance sheet stays investment grade even after the Exact Sciences cash payout, and the company just declared its 410th consecutive dividend, extending a 53-year growth streak.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• Abbott Company Profile: Key Facts Snapshot

• Abbott Investment Thesis

• Abbott Business Model Overview

• Abbott Revenue Analysis

• Quarterly Earnings Guidance, Margins, and Earnings Quality

• EPS Trajectory

• Cash Flow Mechanics

• Balance Sheet Health

• Abbott Segment-by-Segment Teardown

• Major Abbott Competitors

• Abbott Strategic Context

• Abbott Valuation Framework

• Bull, Base, and Bear Case Scenario Analysis

• Key Risks for Abbott

• Catalysts to Watch

• Latest Analyst Price Targets

• My Final Thoughts

• Official Sources and Data

  Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

Abbott (ABT) spent $21 billion of shareholder cash on a colorectal cancer diagnostics maker, cut its own earnings guidance the same day it announced the deal, and then… its stock quietly held up while management delivered two straight beats. Not a fireworks show. A grind higher.

That grind is the thesis.

Abbott isn’t the sexiest name in medtech. It doesn’t have a GLP-1. It doesn’t have a robotic surgery platform stealing headlines.

What it does have is a durable four-legged business, a CGM franchise crossing key scale thresholds, and a newly acquired cancer screening asset that took Diagnostics from a shrinking, COVID-hangover story to a top-line growth engine again.

For investors sizing up ABT for the back half of 2026 and into 2027, the question is whether the Exact Sciences bet, the tariff drag, and the nutrition softness will get in the way of the double-digit EPS story management keeps promising.

Let’s analyze it all.

Subscribe now

Abbott Company Profile: Key Facts Snapshot

Abbott Laboratories is an Illinois-domiciled diversified healthcare company. Founded in 1888 by Dr. Wallace Abbott. Publicly traded on the NYSE under the ticker ABT. Headquarters in Abbott Park, Illinois. And it has been paying dividends without interruption since 1924.

The company operates through four reporting segments after the AbbVie spin-off years ago: Established Pharmaceuticals (branded generics for emerging markets), Nutrition, Diagnostics, and Medical Devices. That’s it. Four buckets. Simple to model on paper, tricky to model in practice because each bucket has its own cyclicality.

Full-year 2025 sales came in at $44.3 billion, up 5.7% reported. Adjusted operating margin was in the mid-23% range. R&D spend hit $2.94 billion for the year, roughly 6.6% of sales, which is on the low side for a medtech and near the middle for a diversified healthcare.

Global employees are north of 114,000 across 160-plus countries.

Company snapshot (Abbott Laboratories, ABT):
- HQ: Abbott Park, Illinois, USA
- CEO / Chairman: Robert B. Ford (since Mar 2020 / Dec 2021)
- Ticker / Exchange: ABT / NYSE
- FY 2025 revenue: $44.3B
- FY 2025 R&D: ~$2.94B
- Segments: Established Pharma | Nutrition | Diagnostics | Medical Devices
- Dividend streak: 53 years (Aristocrat)
- Consecutive quarterly dividends: 410

Chairman and CEO Robert Ford took over as CEO in March 2020, right into the pandemic, and became chairman in December 2021. His 23-year Abbott career has been mostly on the medical devices side, and it shows in the way he talks about the company.

Subscribe now

Abbott Investment Thesis

Why now, and why Abbott specifically

The short version: Abbott is buying a durable, mid-single-digit organic grower for what should be a mid-teens EPS growth story, if the Exact Sciences integration lands. The stock, hovering in a mid-90s to low-100s range through most of 2026, hasn’t fully re-rated for that scenario.

The medium version: Abbott has four independent growth engines and only two of them have to fire well for the earnings model to work. Right now, Medical Devices and Diagnostics are firing. Nutrition is stalled but stabilizing. EPD is quietly ripping in emerging markets.

The long version comes next. Read on.

The four-legged stool argument, revisited

Investors love the “diversification protects you” argument. Fine. But diversification alone isn’t a thesis.

The real point about Abbott is that no single segment can sink it and no single product line can carry it. That’s structurally different from Dexcom (concentrated in CGM), Medtronic (concentrated in devices), or Roche Diagnostics (concentrated in labs). It shapes how the stock trades.

When infant formula blew up in 2022, Abbott absorbed the hit. When COVID testing rolled off in 2023 and 2024, Abbott absorbed the hit. When the FreeStyle Libre gets pricing pressure in Europe, Diagnostics or Structural Heart usually fills the hole. It doesn’t always look pretty inside a quarter, but the annual number keeps grinding.

Subscribe now

The Exact Sciences bet in short

Abbott paid $105 per share in cash for Exact Sciences. Total equity value about $21 billion. Deal closed March 23, 2026. Exact was projected to generate more than $3 billion of revenue this year, most of it from Cologuard, the stool-based colorectal cancer screening test.

Why does Abbott want this?

Because its own Diagnostics segment, minus COVID, was structurally boring. Core lab is a slow grower. Rapid diagnostics was in decline post-pandemic. Adding Cologuard, plus Exact’s Oncotype DX line for cancer treatment decisions, plus a pipeline in MRD (minimal residual disease) and MCED (multi-cancer early detection), immediately turns Diagnostics into the fastest-growing segment inside Abbott.

That’s a business mix shift, not just a bolt-on. Which is what management is actually selling here.

Subscribe now

Abbott Business Model Overview

Selling into three very different types of buyers

Abbott sells into three fundamentally different customer types.

Hospitals and labs pay for its high-end diagnostics and cardiac devices with long procurement cycles. Consumers and pharmacies pay for its Nutrition brands and, increasingly, its over-the-counter Lingo biowearable. And emerging-market physicians and pharmacies pay for EPD’s branded generics with much less pricing power than a US hospital sale.

This matters because each channel has a different sales cycle, gross margin structure, and receivables profile.

When people call Abbott “defensive,” they’re really pattern-matching on the fact that at least one of those channels is usually resilient in any given macro environment.

The recurring revenue quality nobody prices in

A big chunk of Abbott’s revenue is what I’d loosely call annuity-like. Not SaaS. But sticky.

FreeStyle Libre sensors are consumables that a diabetic user replenishes every two weeks. Alinity diagnostics analyzers, once placed in a lab, generate multi-year reagent pull-through. TriClip and MitraClip generate follow-on imaging and echocardiography referrals. Cologuard is recommended for repeat screening on a three-year interval for average-risk adults.

Consumables and reagent pull-through don’t get the same multiple as software recurring revenue. That’s a market inefficiency that Abbott has quietly exploited for two decades.

Rough revenue durability profile (my read):
- Nutrition (Ensure, Similac, Pedialyte): recurring, low switching, brand-driven
- Diabetes Care (Libre + Lingo): consumable-driven, high stickiness
- Structural Heart / EP: procedure-driven, physician preference sticky
- Diagnostics (Alinity + Cologuard): reagent + repeat-testing recurring
- EPD: prescription-driven, emerging market volume growth

R&D that actually converts into launches

Abbott spends about 6-7% of sales on R&D. That looks light next to pure medtech peers like Boston Scientific or Edwards. But the conversion into commercial products has been reasonably efficient in recent years. Volt PFA, AVEIR DR, TriClip, Esprit BTK, Navitor, Libre 3, Lingo. All hit the market inside the last 3 years.

Management flagged more than 15 new growth announcements in 2024 alone as part of its Q4 2024 commentary. The pace hasn’t slowed in 2025 or into 2026.

Abbott Revenue Analysis

Read more

A partial transcript of a private May 2026 investor call attributed to DeepSeek founder Liang Wenfeng leaked in late July, then vanished from Chinese platforms within hours.

The claim getting the most airtime on Wall Street trading desks was blunt. He allegedly told the room that Nvidia’s CUDA moat is “rapidly disintegrating,” and that Chinese labs could pair Huawei silicon with AI-driven code generation and tools like TileLang to bypass Nvidia’s software lock-in inside roughly a year.

For the US investor watching an $81.6 billion quarterly print at Nvidia and wondering how durable it is, that comment is either a hollow flex from a company that often delays its own model launch, or the loudest early warning bell so far.

Either way it deserves a careful analysis.

Recommended - Read Full Reports

Read All Reports

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

What Liang Reportedly Said

The transcript comes from a nearly four-hour closed-door meeting with new shareholders, and multiple reconstructions have surfaced.

The reason it matters is the pace of progress. DeepSeek had earlier disclosed the UE8M0 FP8 numeric format in V3.1, a data format explicitly co-designed with China’s “next-generation domestically produced chips.”

Liang’s own framing was that the US-China gap now sits mostly in compute access, not in algorithms or talent. Which is fine. It’s also, notably, the one gap the CHIPS Act and export controls were specifically designed to widen.

LIANG'S CORE CLAIMS (per the leaked notes)
- 4 x Huawei Ascend 950 ≈ 1 x Nvidia GB300
- Paying 200% more for Ascend clusters "doesn't matter"
- DeepSeek replaced CUDA internally during V3 training
- TileLang + AI-written kernels shrink the CUDA moat

Subscribe now

Why CUDA Was A Moat In The First Place

CUDA is not one thing. It’s a parallel programming model, a set of compilers, a decade of library work (cuDNN, NCCL, TensorRT), and a global developer base that already knows the API.

Nvidia has been reinvesting into that stack since 2006, longer than most of today’s AI startups have existed.

The practical result is that most AI code paths in production quietly assume CUDA underneath.

Even PyTorch, technically hardware-agnostic, has its most optimized kernels written for Nvidia hardware first and everyone else later. Migrating a serious training workload to a new stack used to take a full engineering year.

The catch is that “used to.”

Compiler-driven approaches like OpenAI’s Triton already let developers write GPU kernels in Python without touching low-level CUDA. And Huawei’s answer, CANN, has been open-sourced exactly to shorten the porting distance.

THE STACK, SIMPLIFIED

NVIDIA:   Model  ->  PyTorch  ->  CUDA/cuDNN  ->  GPU
HUAWEI:   Model  ->  MindSpore/PyTorch  ->  CANN  ->  Ascend NPU
DEEPSEEK: Model  ->  In-house compiler + TileLang  ->  Any accelerator

Notice the third row. It’s the interesting one, because it treats the underlying silicon as swappable.

If a model house can compile down to whatever chip it happens to have, the moat is no longer the software layer, it’s just supply.

Subscribe now

The Huawei Side Of The Trade

Huawei laid out a rare three-year roadmap at its September 2025 Connect event.

The Ascend 950PR shipped in Q1 2026, followed by the 950DT, then the 960 planned in 2027 and the 970 in 2028, with each generation roughly doubling compute per chip.

Huawei’s headline system, the CloudMatrix 384, is worth understanding on its own. It packs 384 Ascend 910C chips into a single supernode and, at the rack level, delivers roughly 70% more FLOPS than Nvidia’s flagship GB200 NVL72.

The trade-off is power.

A single CM384 pulls about 560 kW against roughly 145 kW for the NVL72, so on a performance-per-watt basis Nvidia is still the cleaner design.

But, in China, where power is heavily subsidized in strategic corridors and grid buildout is state-directed, that trade-off is more tolerable than it would be in US or Europe.

CLOUDMATRIX 384 vs GB200 NVL72 (system level)

Aggregate FLOPS: CM384 ~1.7x  vs  NVL72 baseline
Memory capacity: CM384 ~3.6x  vs  NVL72
Power draw:      CM384 ~560 kW vs NVL72 ~145 kW
Efficiency:      Nvidia wins per watt by a wide margin

Huawei has also revealed that its next roadmap generation will move to in-house HBM, which is arguably the harder problem than the logic die itself.

Whether SK hynix and Samsung continue to sell HBM into China at scale is the real question, and it’s more of a US State Department question than a technical one.

DeepSeek’s Play, And Why It’s Different

Most of the “China is catching up” coverage focuses on the hardware. The leaked call flips that.

Read more

Executive TL;DR

• Salesforce (CRM) closed fiscal 2026 at $41.5 billion in revenue, up 10% year-over-year, and started fiscal 2027 with an $11.13 billion Q1 that grew 13% (its fastest print in a while).

• Agentforce annual recurring revenue rocketed to $1.2 billion in Q1 FY27, up 205% year-over-year. Still tiny inside a $46B revenue base… but the ramp is hard to ignore.

• The Informatica deal ($8B) closed in November 2025, folding into the Data 360 stack. Management pushed FY27 revenue guidance up to $45.9B–$46.2B.

• Capital return has gone parabolic. A $50 billion buyback authorization, a $25B accelerated share repurchase completed in Q1 FY27, and the dividend was hiked 5.8%.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• Salesforce Company Profile: Key Facts Snapshot

• Investment Thesis for Salesforce (CRM)

• Salesforce Business Model Overview

• Salesforce Revenue Analysis

• Latest Quarterly Earnings Guidance

• Margins, Earnings Quality, and EPS Trajectory

• Cash Flow Mechanics

• Balance Sheet Health

• Segment-by-Segment Teardown

• Major Salesforce Competitors

• Salesforce Strategic Context: The Agentic Enterprise Bet

• Salesforce Valuation Framework

• Bull, Base, and Bear Case Scenario Analysis

• Key Risks for Salesforce

• Catalysts to Watch

• Latest Analyst Price Targets

• The Capital Return Story

• Salesforce’s Product Evolution Timeline

• The Employee and Culture Angle

• Regulatory and Legal Considerations

• Salesforce vs. Its Own Past Self

• Q1 FY27 Detailed Read

• Salesforce as a Platform vs. a Product Company

• What the Q1 FY27 Earnings Call Actually Revealed

• The Informatica Deep Dive

• Dreamforce 2025 Recap

• Beyond the Numbers: The Culture and Governance Story

• Segment Momentum Heading Into H2 FY27

• An Uncomfortable Honest Take

• Comparisons to Prior Tech Cycles

• Recent M&A: The Cadence Question

• Product Roadmap Signals

• Portfolio Positioning for Investors

• The 2026 Layoff Context

• What Successful Execution Looks Like Over the Next Four Quarters

• My Final Thoughts

• Official Sources & Data

  Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

Here’s the thing about Salesforce (CRM) right now. A year ago the story was “can this thing keep growing double digits?” and half the sell-side had penciled in “no, welcome to mid-single-digit software purgatory.”

Then the Q1 FY27 print landed. Thirteen percent growth. Agentforce ARR at $1.2 billion. Slack showing up on nearly half of the seven-figure wins. The narrative flipped inside 90 days.

But shares still trade nowhere near the 2024 highs, which is either a gift or a warning depending on which analyst you follow. As of mid-July 2026, CRM closed near $157, roughly half its all-time peak. That’s a strange place for a business printing 34% non-GAAP margins and $14.4B of free cash flow.

So what is this?

I think it’s the most fundamentally interesting stretch of Salesforce’s history since the Slack acquisition.

The Informatica deal closed. Agentforce hit escape velocity (or at least what looks like it). A brand-new President and COFO in Robin Washington is running capital allocation. And the company just executed the largest accelerated share repurchase in its history.

This deep-dive is a segment-by-segment teardown of it all.

Subscribe now

Salesforce Company Profile: Key Facts Snapshot

Salesforce, Inc. is a San Francisco-headquartered cloud software company… the original “no software” pitch from 1999 aged pretty well, all things considered.

It sells subscription-based customer relationship management applications and, over the past decade, has stitched together a much broader enterprise stack: sales, service, marketing, commerce, integration (MuleSoft), analytics (Tableau), collaboration (Slack), data (Data 360, formerly Data Cloud, now beefed up with Informatica), and its agentic-AI layer, Agentforce.

- Ticker: NYSE: CRM
- Founded: 1999 (Marc Benioff, Parker Harris, Dave Moellenhoff, Frank Dominguez)
- HQ: Salesforce Tower, 415 Mission Street, San Francisco, CA
- Chair & CEO: Marc Benioff
- President & COFO: Robin Washington
- Fiscal year end: January 31
- FY26 revenue: $41.5B  (+10% Y/Y)
- Employees: roughly 76,000 (post 2026 trims)
- Index membership: S&P 500, Dow Jones Industrial Average

Subscribe now

Investment Thesis for Salesforce (CRM)

Let me try to state the investment thesis in short.

The Bull Case in Simple Terms

Salesforce sits on the largest installed base of enterprise sales and service software in the world. It has been printing rising operating margins for three straight years while still growing revenue at a double-digit clip. Free cash flow just crossed $14.4B annually. And on top of all that, agentic AI is showing early revenue traction that could reaccelerate growth if it works.

The “Wait, But…” Complication

Growth had decelerated meaningfully. FY26 was 10%. FY25 was 11%. FY24 was closer to 11% too. That’s a company running in place, not one commanding a premium multiple.

Bulls will point to Q1 FY27’s 13% acceleration and say the trend just inflected. Bears will argue that the FY27 guide of 11% at the midpoint bakes in only about three points of Informatica contribution… meaning underlying organic growth is closer to 7–8%. Not exactly Nvidia numbers.

Where the Thesis Actually Lives

The real question is not “does Salesforce still make money?” (obviously yes) or “is AI a threat?” (obviously yes and no, more on that later).

The question is whether the company can convert its distribution advantage into agentic AI revenue faster than a swarm of startups (and, honestly, Microsoft) can erode the ground beneath it. That’s the whole ballgame.

BULL CASE PILLARS
1. Distribution moat: ~150,000 customers, entrenched in every Fortune 500 vertical
2. Data gravity: With Informatica, Salesforce now sits on the pipes AND the endpoints
3. Agentforce economics: Consumption-priced, so revenue scales with actual usage
4. Capital return: $50B buyback + 5.8% dividend hike = shareholder-friendly
5. Margin expansion: 34%+ non-GAAP margins, still room to run

And a Fun Bit of Historical Perspective

For a company famous for making acquisitions… Slack ($27.7B), Tableau ($15.7B), MuleSoft ($6.5B), then Informatica ($8B)… Salesforce has managed the awkward trick of both being an aggressive acquirer AND still generating a lot of organic momentum.

Whether that dual identity survives contact with agentic AI is the whole point of this analysis.

Subscribe now

Salesforce Business Model Overview

Salesforce is a subscription software company. Which sounds boring until you look at the underlying mechanics.

The Subscription and Support Engine

The vast majority of revenue (~94% in FY26) comes from subscription and support fees. Customers pay per user, per month, typically committing to multi-year contracts.

That contract book creates something called Remaining Performance Obligation (RPO). At the end of Q1 FY27, RPO was $67.9 billion, and current RPO (the portion expected to be recognized over the next 12 months) was $33.6 billion.

That’s a lot of contracted future revenue sitting on the balance sheet, mostly invisible in the P&L on any given day. It’s the reason software analysts obsess over cRPO. If cRPO grows faster than reported revenue, the next 12 months should be strong. If it decelerates, look out.

Q1 FY27 KEY BOOKINGS METRICS
- cRPO: $33.6B, up 14% Y/Y (13% CC)
- RPO: $67.9B, up 11% Y/Y
- Q1 deals >$1M ACV: 98 deals
- Slack attached: ~half of >$1M wins

Subscribe now

Professional Services (the Small Sibling)

The other 6% or so of revenue comes from professional services and other implementation-related fees.

It’s a low-margin business by design (implementation partners like Accenture, Deloitte, and IBM do most of the heavy lifting) and it exists mostly to seed subscription attachment.

Where AI Fits In Pricing

Here’s the thing… Salesforce charges for Agentforce primarily on a consumption basis. Roughly $2 per conversation for the original tier, with newer tiers moving toward outcome-based pricing.

That means revenue does NOT just scale with seats. It scales with usage. Which is why Benioff spends so much time on earnings calls talking about “consumption metrics” now. Different model. Different story if it works.

Multi-Cloud Attach

The killer feature of Salesforce’s model, honestly, is multi-cloud attach.

A customer that starts with Sales Cloud gets sold Service Cloud, then Marketing Cloud, then Data 360, then MuleSoft. Every attachment increases average contract value AND net dollar retention.

This is why net-new logo growth can be modest while total revenue still climbs. Existing customers keep buying more.

Salesforce Revenue Analysis

Read more

Executive TL;DR

• DeepSeek closed its first external funding round in June 2026 at $50B+ valuation, then went right back to market for another round at about $71B, targeting a mainland IPO filing this year for a 2027 debut.

• The V4 family (Pro at 1.6T total / 49B active, Flash at 284B) shipped on April 24, 2026, and unusually, V4 was optimized day-zero for Huawei Ascend, which reshapes the whole China supply-chain conversation.

• Independent evaluators still put DeepSeek about eight months behind the US frontier on aggregate benchmarks, but the price-per-token gap is wider than the capability gap. That’s the whole story.

• No US listing, no US-investor access, growing regulatory bans on government devices, and a governance structure where the founder owns roughly 84%. So the equity is largely a China-onshore theme, not a Nasdaq theme. But it still could hugely impact your US-tech investments.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• DeepSeek Company Profile: Key Facts Snapshot

• The Investment Thesis

• Business Model Overview

• Revenue Analysis (What We Actually Know)

• Margins and Cash Flow

• Segment-by-Segment Teardown

• Major Competitors: Head-to-Head

• Strategic Context: The China AI Stack and Why It Matters

• Valuation Framework

• Bull, Base, and Bear Case Scenarios

• Key Risks

• Catalysts to Watch

• The Nvidia-DeepSeek Feedback Loop

• The Chinese AI Competitive Outlook, in Fuller View

• Architecture Notes: What Makes DeepSeek Technically Interesting

• What Would Change My Mind on DeepSeek

• Cross-Reads for a US Investor’s Portfolio

• My Final Thoughts

• Official Sources and Data

  Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

Something odd happened to DeepSeek’s narrative between January 2025, when it wiped nearly $600 billion off Nvidia in a single session, and today. The shock faded but the company did not.

It kept shipping. V3.1, V3.2-Exp with sparse attention, V4 in April, then a research paper on Manifold-Constrained Hyper-Connections in the summer. Also a first-ever fundraise and an IPO chatter.

For a US-based investor there’s no clean way to own this thing directly. Not yet. But the second-order effects are enormous.

Nvidia’s China revenue math, Alibaba Cloud’s operating leverage, the whole “compute is a moat” thesis in Western AI… all of it moves when DeepSeek moves.

So this in-depth analysis report is a fundamental breakdown of everything that could impact your US-tech investments, as I mentioned earlier.

Let’s get started.

Subscribe now

DeepSeek Company Profile: Key Facts Snapshot

DeepSeek, formally Hangzhou DeepSeek Artificial Intelligence Basic Technology Research, was founded in July 2023 as a spin-out research lab of the Chinese quantitative hedge fund High-Flyer. The parent still funds and largely controls it.

Founder and CEO Liang Wenfeng, holds approximately 84% of the company through a stack of holding entities.

He co-founded High-Flyer in 2015-2016 with Zhejiang University classmates and pivoted the fund’s stockpile of Nvidia A100 and H800 cards into an AI research bet in 2022 and 2023.

Company snapshot
--------------------------------------
Legal name        : Hangzhou DeepSeek Artificial Intelligence
                    Basic Technology Research Co., Ltd.
Founded           : July 2023 (spun out of High-Flyer)
HQ                : Hangzhou, Zhejiang, China
Founder / CEO     : Liang Wenfeng (approx. 84% ownership)
Parent / backer   : High-Flyer Quantitative Investment Mgmt.
Latest valuation  : ~$50B (June 2026 close) / ~$71B (in talks)
Flagship model    : DeepSeek-V4-Pro (1.6T MoE, 49B active)
License           : MIT (weights) + custom model license
IPO status        : Onshore mainland filing targeted 2026,
                    debut targeted 2027
Employees         : Estimated <200 core research staff

Headcount is famously small. Chinese and Western press have reported DeepSeek runs more like a research lab than a normal tech company, with a hiring pool that leans hard on young domestic PhD talent from Tsinghua, Peking University, and Zhejiang. No hiring from overseas. No fancy exec bench.

Which, honestly, is part of the story. Because the entire cost structure that spooked US markets last year rests on a headcount that fits in a single conference room.

Subscribe now

The High-Flyer origin story matters more than people think

Liang did not come out of the standard Chinese Big Tech pipeline. He built High-Flyer as a quant fund that ran on GPUs for trading. Then in 2021, when he ordered thousands of Nvidia A100s for research use, nobody in the domestic AI industry took the order seriously.

That stockpile survived the October 2022 US export ban, because it was already on Chinese soil.

And that’s the reason DeepSeek could train at frontier scale while every other domestic lab was screaming about H100 access.

Governance, in practical terms

DeepSeek is not publicly listed. There is no board of independent directors in the Western sense. High-Flyer is the sole institutional backer through 2025.

The June 2026 raise brought in the first outside strategic investors, though press reports say DeepSeek attached a no-poaching clause that startled some LPs.

For a US investor this governance structure is the single biggest single reason to keep DeepSeek in the “theme, not holding” bucket. Even after IPO, foreign investor access will run through the QFII/Stock Connect regime with all its wonderful frictions.

Subscribe now

The Investment Thesis

You cannot buy DeepSeek stock right now. Let’s just get that out of the way up front.

This analysis is not a company recommendation. It’s a framework for understanding a private company whose model releases dictate second-order moves in your actual portfolio.

That said, here’s my thesis in short: DeepSeek is a bet that inference-cost curves collapse faster than model-quality gaps close, and that open-weight distribution beats closed-weight monetization inside a decoupled China compute stack.

The bull argument

Start with pricing. V4-Flash costs $0.14 per 1M input tokens on cache-miss and $0.28 per 1M output. V4-Pro sits at $0.435 input / $0.87 output.

Compare that to Anthropic Claude and OpenAI GPT-5, where per-token pricing is often 10 to 30 times higher for comparable reasoning workloads.

If you think token demand is elastic (and every enterprise adoption study says it is), whoever undercuts the price floor wins the volume game.

DeepSeek’s 545% theoretical cost-profit ratio claim from early 2025 was aggressive, sure, but even discounted to reality it implies the unit economics are working.

Then there’s the open-weight moat inversion.

Because DeepSeek publishes weights under an MIT-adjacent license, every Chinese cloud (Alibaba Cloud, Tencent Cloud, Baidu, Huawei Cloud) can host and monetize inference without paying DeepSeek anything.

Seems like a bug but it’s a feature. It made DeepSeek the default reasoning-model choice across the Chinese enterprise stack in Q2 2025 and it has not been dislodged, though Qwen is now clawing back share.

The bear argument

Read more

Executive TL;DR

• Bank of America (BAC) posted a knockout Q2 2026 with $9.1 billion in net income, diluted EPS of $1.21 (up 34% year-over-year), and revenue of $31.6 billion (up 15%), with return on tangible common equity reaching 17.0%.

• Sales and trading revenue reached a record $7.1 billion (equities up 70% to $3.6 billion), while investment banking fees jumped 50% to $2.1 billion, showing the fee engine is firing on all cylinders.

• Full year 2026 net interest income is now expected to grow at the upper end of the 6% to 8% range, with average loans up 8% to $1.22 trillion and average deposits reaching $1.97 trillion.

• Capital return remains meaningful: an $40 billion buyback authorization is running, the CET1 ratio sits at 11.2%, and roughly $8 billion was returned to shareholders in Q2 2026 alone.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• Bank of America Company Profile: Key Facts

• Bank of America Investment Thesis

• Bank of America Business Model Overview

• Bank of America Revenue Analysis

• Bank of America Latest Quarterly Earnings and Guidance

• Margins, Earnings Quality, and EPS Trajectory

• Cash Flow Mechanics and Balance Sheet Health

• Bank of America Segment-by-Segment Teardown

• Major Bank of America Competitors

• Bank of America Strategic Context

• Bank of America Valuation Framework

• Bull, Base, and Bear Case Scenario Analysis

• Key Risks for Bank of America

• Catalysts to Watch in H2 2026

• Latest Analyst Price Targets

• Strategic Considerations for Investors

• My Final Thoughts

• Official Sources and Data

  Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

Investors have spent the first half of 2026 watching mega-cap banks trade like industrial conglomerates that quietly stumbled into an artificial intelligence boom.

Bank of America (BAC) is the clearest expression of that story, running a $3.5 trillion balance sheet, throwing off $8 billion of quarterly capital returns, and simultaneously deploying record technology spending across every business line.

The second quarter print on July 14 changed the tone of the conversation.

Every segment grew, the efficiency ratio dropped to 59%, and the trading desk logged the largest quarterly haul in company history.

For investors, the question now is no longer whether the franchise is intact; it’s whether the growth rate now embedded in guidance is sustainable through the back half of the year.

This report walks through the segment mechanics, capital position, competitive dynamics against JPMorgan, Wells Fargo, and Citigroup, the specific catalysts that can either lift or cap the stock during H2 2026 & more

Let’s get started.

Subscribe now

Bank of America Company Profile: Key Facts

Bank of America is one of the four US Global Systemically Important Banks and the second largest US bank by assets.

The company is headquartered in Charlotte, North Carolina, and operates across the United States, its territories, and more than 35 countries.

The firm serves nearly 70 million clients through approximately 3,500 retail financial centers, approximately 15,000 ATMs, and digital banking with approximately 60 million verified digital users. It ranks as the number one small business lender in the United States by the FDIC.

Bank of America is also a global leader in wealth management through Merrill Wealth Management and Bank of America Private Bank, and a leader in corporate and investment banking and trading.

The bank serves 96% of the US Fortune 1,000 and 78% of the Global Fortune 500.

SNAPSHOT (as of Q2 2026)
Total assets: ~$3.5 trillion
Employees: >213,000 (2025 10-K)
Retail financial centers: ~3,500
Verified digital users: ~60 million
Clients served: ~70 million
Countries of operation: >35
Ticker & listing: BAC on NYSE

Founded in its modern form through the 1998 merger of NationsBank and BankAmerica, and enlarged by the 2008 acquisitions of Countrywide and Merrill Lynch, the company today reports through four operating segments: Consumer Banking, Global Wealth and Investment Management, Global Banking, and Global Markets, with an “All Other” reconciling group.

Subscribe now

Bank of America Investment Thesis for H2 2026

The Franchise Value Case

The bull thesis for Bank of America rests on scale, funding, and operating leverage. Average deposits at $1.97 trillion, of which 59% sit in checking accounts, give the bank one of the most durable and lowest-cost funding bases in US banking.

That funding advantage matters because it lets the bank grow loans without racing peers on deposit pricing. Average loans and leases reached $1.22 trillion in Q2 2026, up $88 billion or 8% year-over-year, the ninth consecutive quarterof loan growth.

The scale of the consumer franchise, combined with a market-leading digital stack, creates a moat that is exceptionally difficult to replicate. Peer banks can copy the products, but cannot replicate 60 million verified digital users at the same acquisition cost.

The Earnings Power Case

Second, the earnings power case is now visible. Net interest income of approximately $16.2 billion in Q2 2026 was up 9% year-over-year, and management now guides to the upper end of a 6% to 8% full year growth range.

Fee income has finally rejoined the party. Investment banking fees climbed 50% to $2.1 billion, sales and trading hit a record $7.1 billion, and wealth management revenue grew to $6.9 billion, so BAC no longer relies on rate curves alone to compound earnings.

The efficiency ratio improvement from 63% to 59% year-over-year translated into 6.6% positive operating leverage. That is a meaningful demonstration that technology spending is finally lowering unit costs rather than merely offsetting them.

Subscribe now

The Capital Return Case

Third, capital return keeps compounding per-share metrics. Book value per share of $37.13 grew 8% year-over-year, the $40 billion buyback authorization approved in July 2025 remains active, and the dividend was raised 8% to $0.28 per quarter.

INVESTMENT THESIS PILLARS (H2 2026)
1. Scale funding advantage (~$1.97T deposits)
2. Multi-engine revenue (NII + Trading + IB + Wealth)
3. Positive operating leverage (efficiency to 59%)
4. Capital return velocity ($40B buyback active)
5. Digital moat (Erica, Zelle, CashPro)

What Could Break the Thesis

The thesis breaks if rate cuts arrive faster than expected, if the trading windfall proves cyclical, or if commercial credit deteriorates.

Provision for credit losses of $1.4 billion in Q2 2026 was actually down from $1.6 billion a year earlier, suggesting no imminent deterioration, but the cycle is not over.

Subscribe now

Bank of America Business Model Overview

The Universal Bank Architecture

Bank of America operates a universal banking model that intentionally spans retail deposits at one end and institutional derivatives trading at the other. The design lets the company recycle low-cost deposits into higher-yielding loans and use its balance sheet to underwrite fee-generating capital markets activity.

The economic logic is that these businesses smooth each other over cycles. When rates fall and net interest income compresses, capital markets fee activity typically accelerates, and vice versa. The Q2 2026 print is a case study in that logic working as designed.

Bank of America collects revenue in three principal ways.

• First, net interest income, the spread between the yield on loans and securities and the cost of deposits and wholesale funding.

• Second, noninterest income, which includes trading, investment banking, wealth management fees, service charges, and card income.

• Third, gains on investment securities and other periodic sources.

Where the Money Comes From

For 2025, total revenue of $113.1 billion split into $60.1 billion of net interest income and $53.0 billion of noninterest income. That roughly 53%/47% mix is more diversified than most large US regional banks and closer to the JPMorgan model than to Wells Fargo.

The four reporting segments produce that revenue with very different economics.

Consumer Banking is the deposit gathering and prime consumer credit engine. Wealth Management is the fee compounder anchored to market values. Global Banking mixes lending, treasury services, and investment banking. Global Markets is the trading and origination engine.

2026 REVENUE ENGINE (illustrative Q2 mix)
Net Interest Income ~$16.2B  (~51% of quarterly revenue)
Sales & Trading      ~$7.1B  (record quarter)
Investment Banking   ~$2.1B  (fees, up 50% YoY)
Wealth Mgmt Rev      ~$6.9B  (record segment revenue)
Card, Service, Other  (balance)

Subscribe now

Cost Structure and Operating Leverage

On the cost side, the biggest levers are personnel, technology, and occupancy. Bank of America plans approximately $13 billion in technology spending in 2026 across every line of business, with new capability spend up 44% over recent years.

That technology intensity is what allows a bank to shrink retail branches while growing customers, and to run a trading platform that scaled to a record quarter without a proportional rise in headcount. The efficiency ratio of 59% in Q2 2026 versus 63% in the prior year quarter is the direct result of that model.

The other model feature investors need to understand is the regulatory capital cost of each business. Trading and structured lending carry higher risk-weighted asset densities than consumer deposits, so the mix of capital by segment matters as much as the mix of revenue.

Bank of America Revenue Analysis

Read more

Executive TL;DR

• Tesla (TSLA) posted record Q2 deliveries of 480,126 units and 13.5 GWh of energy storage, yet Q2 GAAP net income fell about 5% year over year with automotive gross margin excluding regulatory credits sliding to 14.6%.

• Capex has more than doubled to roughly $5.79 billion in a single quarter, driving free cash flow negative as Tesla funds six factories, an Optimus line, an in-house chip fab, and Cybercab tooling.

• The autonomy story is finally in production form: Cybercab manufacturing has begun at Gigafactory Texas and the Robotaxi footprint spans Austin, Bay Area, Dallas, and Houston, with seven more metros lined up.

• Shareholders had already approved the $1 trillion CEO pay package with over 75% support, retaining Musk with performance milestones tied directly to Robotaxi, Optimus, and market capitalization.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• Tesla Company Profile: Key Facts Snapshot

• Investment Thesis

• Business Model Overview

• Tesla Revenue Analysis

• Tesla Q2 2026 Earnings Result

• Margins, Earnings Quality, and EPS Trajectory

• Cash Flow Mechanics

• Balance Sheet Health

• Tesla Segment-by-Segment Teardown

• Major Tesla Competitors

• Tesla Strategic Context

• Tesla Valuation Framework

• Bull, Base, and Bear Case Scenario Analysis

• Key Risks for Tesla

• Catalysts to Watch

• Latest Analyst Price Targets

• My Final Thoughts

• Official Sources and Data

  Subscribe now

Introduction

Tesla (TSLA) is no longer trading as an electric vehicle stock in the traditional sense.

Its Q2 2026 print, released on July 22, showed record top line growth alongside compressed margins and outright negative free cash flow, a combination that would sink most automakers; but that management is deliberately engineering a way out.

The reason is a capital pivot toward autonomy, humanoid robotics, and grid scale energy storage.

Investors are being asked to underwrite a multi-year platform bet at exactly the moment the core car business is fighting a federal EV tax credit expiration and intensifying Chinese competition.

That tension defines the setup for the rest of 2026 and beyond for TSLA.

This in-depth fundamental analysis report walks through the financial reality, the segment-by-segment mechanics, the competitive positioning against BYD, Waymo, Rivian, Lucid, Ford, and GM, and the risks and catalysts that will determine whether Tesla’s $25 billion capex year converts into durable shareholder value.

Let’s get started.

Subscribe now

Tesla Company Profile: Key Facts Snapshot

Tesla, Inc. designs, manufactures, and sells electric vehicles, stationary energy storage systems, solar generation products, and, increasingly, autonomy and robotics platforms.

The company operates two reportable segments under its 10-K disclosures: Automotive (vehicles, credits, services, insurance, Supercharging) and Energy Generation and Storage (Megapack, Powerwall, solar, and related software).

Ticker:            TSLA (NASDAQ)
HQ:                Austin, Texas
CEO:               Elon Musk
CFO:               Vaibhav Taneja
Segments:          Automotive | Energy Generation and Storage
FY2025 Revenue:    $94.8 billion
FY2025 Net Income: $3.79 billion (GAAP)
Q2 2026 Revenue:   $28.24 billion (record)
Q2 2026 Deliveries: 480,126 vehicles
Q2 2026 Storage:   13.5 GWh deployed

Tesla’s manufacturing footprint spans Fremont (California), Gigafactory Texas (Austin), Gigafactory Nevada (Sparks), Gigafactory Shanghai, and Gigafactory Berlin-Brandenburg (Grünheide), with an Optimus factory rising at Giga Texas and Semi volume production ramping at Giga Nevada.

Subscribe now

Tesla Investment Thesis

Why the bull case still exists after a margin miss

Tesla’s Q2 2026 top line rose 26% year over year to $28.24 billion, a company record, driven by a delivery rebound after a difficult 2025. That growth is the anchor of the long thesis: unit volume finally re-accelerated after two years of stagnation.

The delivery inflection matters because Tesla’s forward optionality (Robotaxi, Optimus, energy) is priced against a shrinking fleet, not an expanding one. With H1 2026 deliveries running well ahead of H1 2025, the installed base that Tesla can retrofit into a robotaxi network is growing again.

The second pillar is the energy segment, which Tesla’s own Q4 2025 update showed grew 27% in FY2025 to $12.7 billion.

Q2 2026 deployments of 13.5 GWh represent the second highest quarter in company history and a 53% sequential jump.

Where the thesis meets reality

The thesis also assumes Tesla can convert Cybercab and Optimus from concept to cash flow.

Cybercab entered production at Giga Texas in Q2 2026, and Optimus Gen 3 low volume production is targeted for Summer 2026 at Fremont, with high volume ramp planned for 2027.

Tesla’s own capex disclosures signal management is not hedging: 2026 capex is guided above $25 billion, roughly triple historic norms, spread across six major facilities, a Texas chip fab, and the Optimus line.

The bear side of the thesis is equally clean.

Automotive gross margin excluding credits dropped to 14.6% in Q2 2026, capex is exploding, and the $7,500 federal EV credit expired September 30, 2025, removing a durable US demand subsidy.

Subscribe now

Framing the thesis for the rest of 2026

The right way to hold the thesis is as a barbell: automotive is a mature, margin-pressured cash engine funding a portfolio of high-variance bets on autonomy, robotics, and grid storage.

If any two of the three moonshots monetize meaningfully in 2027 to 2028, the current capex phase looks cheap.

If none do, or if Robotaxi scaling stalls, Tesla is a high-multiple automaker with structurally weaker unit economics than in 2022.

That binary quality is the real reason valuation debate is so loud right now.

Bull pillars:  Delivery re-acceleration, Energy 27% growth,
               Robotaxi/Cybercab in production, Optimus Gen 3 ramp
Bear pillars:  Auto margin ex-credits at 14.6%, FCF negative,
               EV tax credit expiration, BYD scale, Musk key-man risk
Swing factor:  Autonomy conversion (miles, safety, geofence pace)

Subscribe now

Tesla Business Model Overview

Vehicle unit economics

Tesla’s core cash flow engine remains vehicle sales.

In Q2 2026, automotive revenue rose 23% year over year to $20.52 billion, with automotive gross margin at 16.9% including credits and 16.3% excluding them, per the shareholder deck.

Q1 2026 automotive gross margin ex-credits was 19.2%, so the sequential compression is real.

The unit economics story of 2026 is that Tesla is trading margin for volume.

The Model Y Juniper refresh is more content-rich (new interior, revised lighting, refreshed hardware) and Tesla is running promotional pricing to clear inventory that ballooned to 27 days at the end of Q1.

The regulatory credit dimension

Regulatory credit revenue has historically been high-margin because Tesla incurs minimal cost to generate ZEV credits. Credits contributed $1.99 billion over the trailing twelve months, down 27.87% year over year as US regulations shift.

The bear implication is straightforward: without credits, Q2 automotive gross margin would sit at 14.6%.

That’s closer to a legacy OEM than the software-margin premium Tesla historically commanded.

Subscribe now

Energy segment as a growth engine

The energy business now sits at the core of Tesla’s re-rating thesis. Storage revenue was $12.7 billion in FY2025, up 27%, and accounted for 13% of the company’s total. Q2 2026 deployments of 13.5 GWh were 41% higher than the same quarter last year and 53% higher sequentially.

The Megapack 3 platform launched with a 20 MWh integrated system that includes inverter and fire protection and cuts thermal bay complexity by 78% versus the prior generation.

That reduces install labor and improves gross margin at the project level.

Services, Supercharging, and insurance

The Services and Other line is a growing but lower-margin bucket that captures used vehicle sales, non-warranty repairs, merchandise, Supercharging revenue, and insurance. Tesla’s Supercharger network reached 8,463 DC fast-charging stations in Q1 2026, up 19% year over year.

The NACS transition has enabled Ford, GM, Rivian, and other OEMs to plug into Supercharger, expanding Tesla’s addressable charging revenue beyond its own fleet.

Insurance remains small but is scaling in states where Tesla has direct authority. Tesla Property & Casualty grew premium volume 9% year over year to $50.8 million in Q1 2026 across the states it currently serves.

Q2 2026 revenue mix (approximation):
Automotive (vehicles + credits + leasing): ~$20.5B
Energy Generation & Storage:               ~$3.9-4.5B
Services & Other:                          Balance
Total:                                     $28.24B

Tesla Revenue Analysis

Read more

Executive TL;DR

• Alphabet (GOOGL) just closed the second quarter of 2026 with $119.8 billion in revenue (up 24% year over year), a 34% operating margin, and Google Cloud revenue jumping 82% to $24.8 billion, marking the fifth straight quarter that the cloud unit posted acceleration.

• The company raised its 2026 capital expenditure guidance to a range of $195 billion to $205 billion, roughly doubling 2025’s spend, and signaled another meaningful increase for 2027 as demand outpaces capacity.

• A record $84.75 billion equity raise priced in June, combined with $242 billion in cash and marketable securities, gives the balance sheet exceptional flexibility to fund the AI buildout.

• Search revenue grew 17%, YouTube ads grew 13%, Waymo scaled to roughly 500,000 paid rides per week, and Gemini 3 continues to reshape both consumer surface area and enterprise tokens.

Recommended - Read Latest Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• Alphabet Company Profile: Key Facts Snapshot

• Investment Thesis (2026 and beyond)

• Business Model Overview

• Alphabet Revenue Analysis: Segment-by-Segment Teardown

• Q2 2026 Earnings Report: The Full Read-Through

• Margins, Earnings Quality, and EPS Trajectory

• Balance Sheet Health

• Cash Flow Mechanics

• Alphabet Strategic Context

• Alphabet Competitors: Detailed Comparisons

• Alphabet Valuation Framework

• Bull, Base, and Bear Case Scenarios

• Key Risks for Alphabet

• Catalysts to Watch

• Alphabet AI Infrastructure: The $200 Billion Question

• Google Cloud Deep Dive

• The Gemini Stack

• The Antitrust Overhang

• Waymo: The Under-Modeled Asset

• Latest Analyst Price Targets

• The Equity Raise: What It Signals

• Operational Efficiency and Cost Discipline

• Strategic Priorities Alphabet Has Named

• Sensitivity Analysis for the Rest of 2026

• Global Regulatory Snapshot

• Capital Return Program

• Long-Duration Optionality: The R&D Portfolio

• The Advertising Business in the AI Era

• My Final Thoughts

• Official Sources & Data

  Subscribe now

Introduction

Alphabet (GOOGL) just reported the most consequential quarter in its recent history, and the market’s reaction has forced every serious investor to rebuild their model.

Revenue growth of 24%, Google Cloud accelerating to 82%, a 34% operating margin at scale, and a $195 to $205 billion capex plan all landed inside one earnings release.

The narrative around Alphabet has now shifted from a defensive Search monopoly under antitrust siege into an AI infrastructure operator with an accelerating cloud franchise and an autonomous mobility business that produced its first million-ride month.

Yet the same quarter also saw the company signal supply-constrained cloud growth, “modest margin pressure” from third-party capacity leases, and the largest equity offering in corporate history.

For investors weighing GOOGL against the rest of the Magnificent Seven, the questions are no longer about whether AI monetization is real.

They are about the returns on this unprecedented capex cycle, the durability of Search economics as AI Overviews reshape the query surface, and how much operating leverage remains once the buildout normalizes.

Let’s analyze everything.

Subscribe now

Alphabet Company Profile: Key Facts Snapshot

Alphabet Inc. is the Mountain View–headquartered holding company created in the 2015 reorganization that separated Google’s core internet services from a portfolio of longer-horizon bets in mobility, life sciences, and connectivity.

The company trades under two share classes, GOOGL (Class A, one vote) and GOOG (Class C, no vote), both on the Nasdaq.

Sundar Pichai serves as CEO of both Google and Alphabet, and Anat Ashkenazi took the Chief Financial Officer seat in mid-2024 after nearly three decades at Eli Lilly. The board is chaired by John L. Hennessy, and co-founders Larry Page and Sergey Brin retain effective voting control through Class B super-voting shares.

Reported segments are Google Services (Search, YouTube, Subscriptions/Platforms/Devices), Google Cloud (GCP plus Google Workspace), and Other Bets, which contains Waymo, Verily, Isomorphic Labs, and several smaller units.

The company generated full-year 2025 revenue of $402.8 billion, and headcount stood at 196,068 employees as of March 2026.

Alphabet Inc. quick reference
Ticker(s): GOOGL / GOOG  (Nasdaq)
Segments: Google Services · Google Cloud · Other Bets
CEO: Sundar Pichai   CFO: Anat Ashkenazi
FY2025 revenue: $402.8B
Cash & marketable securities (Jun 30, 2026): $242.5B
Employees (Mar 31, 2026): 196,068

The scale of the company is easy to lose track of.

Alphabet closed calendar 2025 with revenue over $400 billion, generated more free cash flow than the market cap of most public companies, and now spends more on physical infrastructure than the US federal government spends on non-defense discretionary science research.

Subscribe now

Alphabet Investment Thesis (2026 and beyond)

The AI compounding thesis

The core bull thesis rests on Alphabet’s rare combination of proprietary silicon, world-class models, and a two-sided distribution machine reaching billions of end users and millions of businesses.

Every layer of the AI stack now runs through infrastructure Alphabet either owns or influences.

Ironwood, the seventh-generation TPU, delivers roughly ten times the peak performance of the prior generation and is purpose-built for large-scale inference.

That silicon lineage, paired with Gemini’s rapid model cadence, means Alphabet does not need to lease Nvidia (NVDA) GPUs at merchant prices to serve its own workloads.

Vertical integration snapshot
• Silicon: TPU v7 Ironwood + Axion CPUs
• Models: Gemini 3 Pro, Gemini 3 Deep Think, Gemini 3.1 Flash
• Platforms: Search, YouTube, Android, Workspace, GCP
• Distribution: 2.5B+ AI Overviews users, 3B+ Android devices

Subscribe now

Search is not being disintermediated, it’s being repackaged

Bearish analysts spent 2024 and 2025 predicting that generative AI would erode Google Search economics.

What the data since Gemini 2.5 and Gemini 3 launched shows is very different.

Search & Other revenue grew 17% year over year in Q2 2026, an acceleration from the 19% clip in the prior quarter and a meaningful step up from the low-double-digit growth Search posted through most of 2023.

The AI Overviews product now reaches billions of users each month, and the newer AI Mode surface is running as an agentic experience layered on top of Search.

Query volume has not compressed, and monetization density on assistive queries has held up in a way that few analysts modeled a year ago.

Cloud has moved from a check-the-box workload to an AI-native destination

Google Cloud’s 82% growth rate in Q2 2026 is the highest annual growth Alphabet has ever reported for the segment, and it comes on a $24.8 billion base, not a small one.

The $462 billion backlog reported after Q1 nearly doubled sequentially, which implies

Read more

Executive TL;DR

• Johnson & Johnson (JNJ) closed the first half of 2026 with worldwide sales of $49.4 billion, and management raised full-year guidance to a midpoint of $101.1 billion, officially clearing the $100 billion revenue threshold for the first time.

• The Innovative Medicine engine is outrunning its Stelara loss-of-exclusivity headwind, with Darzalex crossing $4.21 billion and Tremfya surging 72.5% year over year to roughly $2.0 billion in Q2 2026 alone.

• MedTech delivered a softer 4.5% reported growth in Q2 as Abiomed sales weighed on performance, while the planned DePuy Synthes Orthopaedics spinoff sets up a leaner, faster-growing device franchise.

• Capital return is intact: the board approved a 3.1% dividend increase marking the 64th consecutive annual raise, and full-year adjusted EPS guidance was lifted to a $11.50 to $11.65 range.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• Johnson & Johnson Company Profile: Key Facts

• Johnson & Johnson Investment Thesis

• Johnson & Johnson Business Model Overview

• Johnson & Johnson Revenue Analysis

• Latest Quarterly Earnings and Guidance

• Margins and Earnings Quality

• EPS Trajectory

• Cash Flow Mechanics

• Balance Sheet Health

• Johnson & Johnson Segment-by-Segment Teardown

• Major Johnson & Johnson Competitors

• Johnson & Johnson Strategic Context

• Johnson & Johnson Valuation Framework

• Bull, Base, and Bear Case Scenarios

• Key Risks for Johnson & Johnson

• Catalysts to Watch

• Analyst Price Targets

• My Final Thoughts

• Official Sources and Data

  Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

Johnson & Johnson (JNJ) sits at an inflection point that few of its peers can claim.

The Stelara patent cliff, once billed as an existential threat, has been absorbed inside two quarters, and management has already flipped the narrative from “defending” 2026 to raising both revenue and adjusted EPS guidance twice in a row.

For investors watching the healthcare sector, the second half of 2026 matters because it will test whether the post-Kenvue, post-Stelara Johnson & Johnson can compound at mid-single-digit rates while funding a $14.6 billion neuroscience deal, a $13.1 billion cardiovascular deal, and a full Orthopaedics separation.

This report walks through the segments, the drugs, the devices, the competitive set, the valuation, and the risks with the granularity you need to make informed decision.

Let’s get started.

Subscribe now

Johnson & Johnson Company Profile: Key Facts

Johnson & Johnson is the world’s most diversified healthcare company by revenue, now operating as a two-segment business focused on Innovative Medicine (branded prescription drugs) and MedTech (medical devices).

The company was founded in 1886, is headquartered in New Brunswick, New Jersey, and completed its separation of the Consumer Health business Kenvue in August 2023.

That structural shift is the single most important context for reading any comparison to pre-2023 financials.

Ticker: NYSE:JNJ
Exchange: New York Stock Exchange
Headquarters: New Brunswick, New Jersey, USA
Founded: 1886
CEO: Joaquin Duato
Segments: Innovative Medicine, MedTech
Employees: ~138,000 (as of latest 10-K)
Consecutive dividend increases: 64 years
Recent quarterly dividend: $1.34 per share

The company’s market capitalization sits near $606.67 billion, placing it among the two largest healthcare companies globally alongside Eli Lilly.

The post-Kenvue Johnson & Johnson is a materially different business than what long-tenured shareholders held five years ago.

Consumer products revenue no longer smooths the top line, so quarterly results now reflect the volatility of drug launches and device cycles more directly.

Management has spent the last three years redeploying separation proceeds into pharma and device tuck-ins rather than a mega-merger, a choice that has kept net debt manageable and preserved a AAA-adjacent credit profile.

Subscribe now

Johnson & Johnson Investment Thesis

The Core Investment Case

The investment thesis rests on three legs.

First, the Innovative Medicine portfolio has cleared the Stelara loss-of-exclusivity air pocket faster than management guided at the start of 2026.

Second, MedTech’s cardiovascular pillar built through the Shockwave Medical acquisition is compounding at double-digit rates, offsetting slower orthopaedics growth ahead of the spinoff.

Third, the balance sheet still generates enough free cash flow to fund a 64-year dividend streak plus buybacks plus opportunistic M&A.

Subscribe now

Why H2 2026 Is a Meaningful Window

H2 2026 is when several catalysts stack. Icotrokinra is progressing toward regulatory milestones for psoriasis, Tremfya continues to expand into inflammatory bowel disease indications, and nipocalimab is being positioned as a differentiated FcRn asset.

The Caplyta franchise, added through the Intra-Cellular Therapies acquisition that closed in April 2025, is scaling into major depressive disorder after its November 2025 FDA approval.

Key thesis drivers to watch in H2 2026:
- Continued Darzalex share gains in multiple myeloma
- Tremfya IBD ramp against Skyrizi and Rinvoq
- Caplyta MDD launch trajectory (post Nov 2025 approval)
- Shockwave IVL adoption in coronary and peripheral indications
- Ottava robotic surgery clinical trial readouts
- Progress toward DePuy Synthes Orthopaedics separation

Subscribe now

Defensibility of the Thesis

The Innovative Medicine segment has more than ten assets that either exceed $1 billion in annual sales or are on the path to do so, reducing concentration risk that plagues single-product biotech peers.

Multiple oncology growth drivers such as Darzalex, Carvykti, Tecvayli, Talvey, and Rybrevant are all in various stages of label expansion.

MedTech’s diversification across cardiovascular, surgery, orthopaedics, and vision provides a second, largely uncorrelated revenue stream. When drug pricing pressure hits pharma, procedure volumes usually normalize; when hospital capex is constrained, drug scripts still fill.

The company’s committed $55 billion U.S. investment covering manufacturing, R&D, and technology through 2029 aligns the company with domestic policy incentives at a moment when tariff and drug pricing risk are elevated for globally exposed peers.

Subscribe now

Johnson & Johnson Business Model Overview

Two-Segment Architecture

Post-Kenvue, Johnson & Johnson runs a two-segment business.

Innovative Medicine covers branded, prescription pharmaceuticals across oncology, immunology, neuroscience, cardiovascular and metabolism, infectious disease, and pulmonary hypertension.

MedTech covers medical devices grouped into cardiovascular, surgery, orthopaedics, and vision.

The vision business includes both consumer contact lenses and surgical cataract equipment, which is why it sometimes gets grouped separately in analyst models.

Innovative Medicine therapeutic areas:
- Oncology (Darzalex, Erleada, Carvykti, Tecvayli, Talvey, Rybrevant, Balversa, Akeega)
- Immunology (Tremfya, Simponi, Remicade, Stelara legacy)
- Neuroscience (Spravato, Caplyta, Invega Sustenna/Trinza/Hafyera)
- Cardiovascular/Metabolism (Xarelto, Opsumit, Uptravi)
- Infectious Disease and Pulmonary Hypertension

Subscribe now

How Revenue Is Generated

In Innovative Medicine the revenue model is patent-protected branded drug sales, priced through payer contracts in the US and largely tender-driven abroad. Gross margins on branded drugs typically run above 80% before rebates and access programs.

MedTech revenue is a mix of consumable sales tied to procedures (staplers, ablation catheters, intraocular lenses, IVL catheters) and capital equipment sales such as robotic platforms and cardiac support pumps. The consumable-to-capital ratio favors consumables, which supports recurring revenue quality.

The Innovative Medicine segment operates under adjusted income-before-tax margins near 42.5% in Q2 2026, a level that reflects the drug portfolio’s premium status.

Geographic Mix

Roughly half of the company’s revenue is generated in the United States. International markets include Europe, Japan, and China as the largest contributors, with emerging market exposure across Latin America, Southeast Asia, and the Middle East.

The US revenue skew is more pronounced in Innovative Medicine than in MedTech, which reflects US pharmaceutical pricing.

This creates a specific exposure to Medicare drug price negotiation policy and to the Inflation Reduction Act mechanisms.

Johnson & Johnson Revenue Analysis

Read more

The AI hardware race just got one of its most consequential launches of the year.

Advanced Micro Devices (AMD) uses the timing of its upcoming Advancing AI 2026 keynote to unveil Helios, its first fully integrated rack-scale AI system, and simultaneously confirmed that Microsoft Azure will deploy it at scale.

Microsoft (MSFT) joins Meta (META), OpenAI, and Oracle (ORCL) in the Helios customer roster, giving AMD an unusually deep bench of hyperscale buyers before a single production rack has shipped.

For investors watching the data center silicon story, this is no longer a question of whether AMD can pressure Nvidia (NVDA) at the accelerator level. It’s now a contest with different economics and a very different partner list.

Let’s analyze the strategic angles from an investor’s point of view.

Recommended - Read Full Reports

Read All Reports

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

What Actually Happened on July 20?

Microsoft announced to “ramp AMD Helios at scale on Azure” to power frontier-model inference for both its own services and external AI customers, per the joint announcement from Santa Clara.

Shipments to Microsoft and other named customers are slated to begin in the second half of 2026. That’s the same window guided at CES earlier this year, so there is no schedule slippage baked into this deal.

Announcement date: July 20, 2026
Product: AMD Helios Rackscale Solution
Silicon: MI455X GPUs + 6th Gen EPYC "Venice" CPUs + Pensando "Vulcano" NICs
First shipments: 2H 2026
Named customers to date: Microsoft, Meta, OpenAI, Oracle

The expansion goes beyond GPUs.

Azure is also adding two new virtual machine families, HDv2 for agentic AI and HXv2 for semiconductor design, both built on the Venice EPYC processors. Pensando DPUs are being woven deeper into Azure Boost networking.

Subscribe now

Inside the Helios Rack

The engineering specs are also one of the reasons what make this launch consequential.

A single Helios rack integrates 72 Instinct MI455X GPUs into a double-wide OCP Open Rack Wide chassis, sharing a common power hub and liquid-cooling loop.

Each MI455X carries 432 GB of HBM4 memory, pushing rack-level memory capacity to a figure that dwarfs prior generations.

AMD Helios Rack, key specs
GPUs per rack:            72 x Instinct MI455X
FP4 compute:              2.9 exaFLOPS
FP8 compute:              1.4 exaFLOPS
HBM4 memory (per rack):   31 TB
Per-GPU bandwidth:        19.6 TB/s
Scale-up bandwidth:       260 TB/s (UALink over Ethernet)
Scale-out bandwidth:      43 TB/s (Ultra Ethernet)

Also, the design deliberately leans on open standards.

UALink handles GPU-to-GPU scale-up, Ultra Ethernet handles cross-rack scale-out, and the mechanical chassis follows the OCP Open Rack Wide specification that

Read more

Executive TL;DR

• Oracle (ORCL) closed fiscal 2026 with record revenue of $67.4 billion, up 17%, and cloud revenue of $34.0 billion, up 39%, with Oracle Cloud Infrastructure (IaaS) alone growing 77% to $18.1 billion.

• Remaining Performance Obligations ended Q4 at $638 billion, up 363%, a backlog roughly ten times larger than annual revenue and one of the largest ever disclosed by a public software company.

• Fiscal 2026 capital expenditures reached $55.7 billion, pushing free cash flow to negative $23.7 billion and forcing a $45 to $50 billion equity and debt financing plan for calendar 2026.

• The stock off more than 60% from its September 2025 peak of $345.72, so the debate for investors is whether the RPO conversion path justifies the balance sheet stretch and the capex intensity.

Recommended - Read Full Reports

Read All Reports

Table of Contents

• Executive TL;DR

• Introduction

• Oracle Company Profile: Key Facts

• Oracle Investment Thesis

• Oracle Business Model Overview

• Oracle Revenue Analysis

• Latest Quarterly Earnings and Guidance

• Margins and Earnings Quality

• EPS Trajectory

• Cash Flow Mechanics

• Balance Sheet Health

• Oracle Segment-by-Segment Teardown

• Major Oracle Competitors

• Oracle Strategic Context

• Oracle Valuation Framework

• Bull Base and Bear Case Scenario Analysis

• Key Risks for Oracle

• Catalysts to Watch

• Sensitivity Analysis on Key Assumptions

• Capital Allocation and Shareholder Returns

• Historical Context and What’s Different Now

• The Stock Price Context

• Governance and Insider Activity

• Environmental and Operational Considerations

• My Final Thoughts

• Latest Analyst Price Targets

• Official Sources and Data

  Subscribe now

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

Oracle’s fiscal 2026 numbers are the sharpest before-and-after in enterprise software history.

Twelve months ago the company had a contracted backlog worth roughly one and a half years of revenue. Today that backlog sits at $638 billion, or nearly ten times annual sales, because a handful of hyperscale AI customers signed multi-year compute contracts that reset the base case for the entire company.

The complication is that Oracle is paying cash now to earn revenue later.

Capital expenditures ran $55.7 billion in FY2026, management has guided to roughly $70 billion for fiscal 2027, and long-term debt has climbed above $100 billion. The market is asking whether this ends like AWS at Amazon in 2015 or like WeWork in 2019.

That’s why this fundamental analysis matters right now.

The June 10, 2026 Q4 print landed the stock down about 10% on the day, and shares have since drifted toward 52-week lows near $121, giving investors a rare chance to buy an AI infrastructure incumbent at valuations that no longer assume flawless execution.

Let’s get started.

Subscribe now

Oracle Company Profile: Key Facts Snapshot

Oracle is a US-headquartered enterprise software and cloud infrastructure company incorporated in Delaware, with corporate offices in Austin, Texas.

It operates a portfolio spanning databases, ERP and HCM applications, industry-specific software (including electronic health records via Cerner), and Oracle Cloud Infrastructure (OCI).

The company is led by two co-CEOs, Clay Magouyrk and Mike Sicilia, both promoted from within on September 22, 2025 when longtime CEO Safra Catz was elevated to Executive Vice Chair of the Board.

Founder Larry Ellison remains Chairman and Chief Technology Officer and continues to set product direction, particularly around OCI and AI.

Company snapshot (as of July 19, 2026)
Ticker:                    ORCL (NYSE)
Fiscal year end:           May 31
FY2026 revenue:            $67.4 billion
FY2026 GAAP net income:    $17.1 billion
FY2026 GAAP EPS:           $5.83
Employees:                 ~162,000 (per FY2026 10-K)
Co-CEOs:                   Clay Magouyrk, Mike Sicilia
Chairman & CTO:            Larry Ellison
Executive Vice Chair:      Safra Catz
Headquarters:              Austin, Texas
Recent price:              ~$126
52-week range:             ~$121 to $345.72

Oracle’s fiscal 2026 10-K was filed on June 22, 2026, and the year showed 4.2 million hours of employee training with an average of roughly 2.6 hours of online learning per employee, an indicator of the workforce retooling underway to run a hyperscaler-sized fleet.

The stock last closed at $126.41 on July 17, 2026, a level not seen since April 2025 and roughly 63% below the September 2025 all-time high.

Subscribe now

Oracle Investment Thesis

The bull case in one sentence

Oracle has already sold roughly ten years of future OCI capacity to the world’s most capital-rich AI companies, and if it can build and light up that capacity on time, the revenue and EPS ramp through fiscal 2029 is essentially contracted.

The unusual asymmetry created by RPO

Enterprise software companies usually forecast on a rolling four-quarter book-to-bill basis.

Oracle now has more than a decade of visibility for its infrastructure business because the $638 billion RPO figure reflects signed, non-cancelable contracts that will convert to revenue over the life of the underlying deals.

The mix inside that backlog matters even more than the headline.

Larry Ellison explicitly named AMD, Meta, NVIDIA, OpenAI, TikTok and xAI as the customers behind the buildout that Oracle is financing.

These are counterparties with either enormous cash positions or backing from investors with enormous cash positions.

RPO trajectory (Oracle disclosures)
FY2025 year-end:   ~$138 billion
Q1 FY2026:         $455 billion (+359% YoY)
Q2 FY2026:         $523 billion
Q3 FY2026:         $553 billion (+325% YoY)
Q4 FY2026:         $638 billion (+363% YoY, +$85B sequential)

Why the market is skeptical anyway

The counter-argument is that RPO is not cash, and Oracle has committed to spending real money right now to earn contracted revenue over the next five to ten years.

Fiscal 2026 free cash flow was negative $23.7 billion, a swing of roughly $23 billion versus fiscal 2025. Long-term debt has surpassed $100 billion as of February 2026, 24% higher year over year, and the calendar 2026 financing plan will add another $45 to $50 billion of gross proceeds.

The thesis becomes a bet on execution timing.

Every quarter of delay in bringing capacity online is a quarter of interest expense without matching revenue. That is why the June 10 print, despite record numbers, triggered a selloff.

Ellison’s own framing

At the Q3 FY2026 call, Larry Ellison reiterated that Multicloud Database revenue grew 531% year over year and AI infrastructure revenue grew 243% year over year, calling both units capacity-constrained rather than demand-constrained.

His argument is that Oracle can convert RPO into revenue as fast as it can build, and the building is the only binding constraint.

Subscribe now

Oracle Business Model Overview

The four-legged stool

Oracle reports revenue across four segments: Cloud services and license support, Cloud license and on-premise license, Hardware, and Services. The company also breaks out cloud revenue by IaaS versus SaaS as an operational disclosure.

FY2026 revenue by reporting line (in $ millions)
Cloud services & license support:   $47,411
Cloud license & on-premise license: $ 5,660  (approx.)
Hardware:                            $ 3,084
Services:                            $ 5,743
Software (traditional):              $24,541

The economics of these lines are very different. Software license and support carries GAAP operating margins comfortably above 80%. OCI infrastructure carries much lower gross margins at current utilization but is where nearly all the incremental growth is landing.

Subscribe now

The compounder inside the hyperscaler

Beneath the OCI headlines lives a resilient legacy business.

Oracle’s on-premise database and applications maintenance revenue continues to renew at high rates because the switching costs of a mission-critical Oracle Database are substantial.

That base funds the cash-flow gap between OCI capex and OCI revenue, though not without help from debt and equity issuance.

Why the transition is different this time

Oracle has attempted cloud transitions before, and the market punished it for lagging AWS, Azure, and Google Cloud.

The current cycle is different because Oracle is selling raw AI training and inference capacity to hyperscalers and model builders, not competing head-on for general-purpose enterprise workloads.

That’s a more capital-intensive business but one where the counterparty risk is concentrated in a handful of well-capitalized names.

Oracle Revenue Analysis

Read more

On July 14, 2026, shares of International Business Machines (IBM) suffered the worst single-day collapse in the company’s 115-year listed history.

The stock plunged roughly 25% before recovering slightly by the close, with an intraday move that surpassed even Black Monday, when Big Blue fell 23.7% on October 19, 1987.

The move erased about $69 billion in market value in a single session, one of the largest single-day dollar wipeouts a Dow component has ever absorbed outside of a systemic crash.

For a company routinely described as a defensive tech name, this was an ambush.

And unlike 1987, there was no macro crash to blame. The catalyst was internal, specific, and worded in a way Wall Street rarely forgets: CEO Arvind Krishna said IBM “faltered.”

Recommended - Read Full Reports

Read All Reports

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

What Actually Happened: The Pre-Earnings Warning

Before the market opened on Tuesday, IBM did something it almost never does. It released preliminary Q2 numbers a full week ahead of the scheduled July 22 report.

Preliminary Q2 revenue came in at $17.2 billion, up just 1%, versus the $17.86 billion consensus. Adjusted EPS was $2.93 against a $3.01 estimate, and GAAP EPS landed at $2.27.

IBM Q2 2026 (Preliminary) — Snapshot
- Revenue: $17.2B  (est. $17.86B)  → miss of ~$660M
- Non-GAAP EPS: $2.93  (est. $3.01)
- GAAP EPS: $2.27
- YoY revenue growth: ~1%
- Segment: Software +5%, Red Hat +11%, Consulting ~flat
- Full report scheduled: July 22, 2026

The scale of the reaction was driven less by the miss itself and more by the reason for it. A shortfall of roughly $660 million on revenue does not, on its own, justify erasing a market cap larger than the entire enterprise value of Kraft Heinz.

Why the Sell-Off Was So Violent

In his letter, Krishna explained that in the final weeks of June, enterprise clients redirected capital spending away from software and toward “servers, storage, and memory purchases to secure supply-constrained infrastructure ahead of expected price increases.”

Put plainly, customers pulled dollars out of software renewals and consulting engagements and shoved them at memory chips and AI-ready hardware.

That’s not a temporary hiccup but a budget reallocation that could persist as long as the AI infrastructure buildout continues.

Krishna also acknowledged execution problems.

Numerous large deals failed to close on the expected timelines, which he called the “majority of our shortfall.” Language like “faltered” and “did not adapt and move quickly enough” from a Fortune 50 CEO is rare, and the market treated it as such.

The 1987 Comparison

Since IBM’s public trading records begin, Tuesday’s decline is its worst on record. The previous benchmark was Black Monday, when the Dow fell 22.6% and IBM lost 23.7% in a systemic panic that spread across every global exchange.

The 2026 fall is worse in percentage terms and vastly worse in dollar terms. What makes it more striking is context.

In 1987, IBM was a part of the “everything collapse”. In 2026, IBM collapsed while the Nasdaq 100 was up 1.08% on a benign inflation print. This was not a market-wide contagion but an IBM event, with clear spillover.

Then vs Now
- Oct 19, 1987: IBM −23.7%, Dow −22.6% (systemic crash)
- Jul 14, 2026: IBM ≈ −25%, Nasdaq 100 +1.08% (idiosyncratic)
- 2026 dollar loss (IBM): ~$69 billion in a single session

The AI Displacement Question: Is Software Being Cannibalized?

The most uncomfortable read of the miss is what it says about enterprise software spending in an AI capex boom.

Memory suppliers such as Micron and SK Hynix have been aggressive beneficiaries of the AI hardware cycle. When CFOs face fixed IT budgets, every dollar spent on GPUs, storage arrays, or high-bandwidth memory is a dollar not spent on new software seats or consulting hours.

Krishna partly disagreed. He told CNBC’s Sara Eisen that customer caution around Anthropic’s new model, “Mythos,” was pushing buyers to

Read more

Something unusual is happening inside the world’s most recognized beverage empire.

A 140-year-old soda giant just posted 12% revenue growth in a single quarter while much of the packaged food industry is being reshaped by GLP-1 obesity drugs, tariffs, and a generational shift away from sugar.

Coca-Cola (KO) is not the same company it was five years ago. Under a CEO succession plan that installed Henrique Braun as CEO effective March 31, 2026, the business is quietly repositioning itself around dairy, hydration, and coffee, while shedding capital-heavy bottling assets across Africa and India.

For investors trying to make sense of a stock that continues to defy consumer-staples gravity, the story is more complex than “soda is dying.”

The following analysis dissects the strengths, weaknesses, opportunities, and threats shaping Coca-Cola through 2026 and beyond.

QUICK SNAPSHOT (KO, as of latest reported quarter)
- FY 2025 Net Revenue: $47.9 billion
- FY 2025 Comparable EPS: $3.00
- Q1 2026 Net Revenue: $12.5 billion (+12%)
- Q1 2026 Comparable Operating Margin: 34.5%
- 2026 Guidance: Organic revenue growth 4%-5%
- Dividend: 64th consecutive annual increase (Feb 2026)
- Billion-dollar brands: 32

Recommended - Read Full Reports

Read All Reports

The Coca-Cola Business Model in 2026: A Concentrate Powerhouse

Before dissecting the SWOT, it helps to understand that Coca-Cola does not primarily sell finished drinks. It sells concentrates and syrups to a franchised bottling network, and monopolizes global brand ownership, marketing, and R&D.

This architecture is central to every strength and every risk that follows.

In Q1 2026, concentrate sales grew 8% while price/mix contributed the remaining organic uplift. The system now spans more than 200 bottling partners and roughly 950 production facilities, sold across more than 200 countries and territories.

Bottling Investments, once 52% of net revenues in 2015, dropped to just 12% of net revenues in 2025, according to the company’s own segment disclosures. That’s the single most important structural change in Coca-Cola over the past decade.

COCA-COLA REVENUE MIX EVOLUTION
- 2015 Bottling Investments share: ~52%
- 2025 Bottling Investments share: ~12%
- Direction of travel: asset-light, higher margin
- Result: reinvestment capacity flows to brands + M&A

Subscribe now

Strengths

Unrivaled Brand Equity and Global Distribution

The single most durable strength in this business is not any one product. It’s the fact that a red-and-white logo is legible in dialects that share almost nothing else. The company operates in more than 200 countries, reaching more consumers than any single social media platform.

The portfolio now spans 32 billion-dollar retail brands, including Coca-Cola, Sprite, Fanta, Minute Maid, Powerade, Dasani, Costa, Fairlife, Simply, and Topo Chico. That diversification cushions the parent brand against category rotation.

The FY25 value share data from the company’s own investor materials underscores the dominance: approximately 50% of the global sparkling soft drinks category, 20% of juice/value-added dairy/plant-based, 20% of water/sports/coffee/tea, and 35% of the energy category via the Monster equity stake.

FY25 TCCC VALUE SHARE BY CATEGORY (company data)
- Sparkling Soft Drinks: ~50%
- Juice, Value-Added Dairy, Plant-Based: ~20%
- Water, Sports, Coffee, Tea: ~20%
- Energy: ~35% (includes Monster equity)

Fortress Margins Compounding Higher

Operating margins have expanded through the refranchising cycle. In Q1 2026, reported operating margin hit 35.0%, up from 32.9% a year earlier, and comparable operating margin (non-GAAP) climbed to 34.5% from 33.8%.

Comparable EPS in Q1 2026 grew 18% to $0.86, a step change unusual for a mature staple. It confirms that mix, pricing, and productivity are still doing real work.

Full-year 2025 net revenues rose 2% to $47.9 billion, with organic revenue up 5% and comparable EPS of $3.00. That translates to price/mix of about 4% and volume growth of about 1% for the year.

Subscribe now

Cash Machine and Dividend Aristocrat

The 2026 dividend hike marked Coca-Cola’s 64th consecutive annual increase, one of the longest streaks in the S&P 500. The Board authorized a quarterly dividend of $0.5300 per share, up $0.02.

Full-year 2026 guidance points to free cash flow of about $12.2 billion, from $14.4 billion in operating cash flow less $2.2 billion in capex. This is the mechanism that funds dividends, share buybacks, and bolt-on M&A simultaneously.

For income-focused portfolios, the payout is unusually resilient because it is funded from a concentrate business with limited working capital drag, rather than from a commodity manufacturer’s inventory cycle.

CAPITAL RETURN PROFILE (KO, 2026 guidance)
- Cash from Operations: ~$14.4B
- Capital Expenditures: ~$2.2B
- Free Cash Flow: ~$12.2B
- Dividend Streak: 64 consecutive annual increases

An Asset-Light, Refranchised Operating Model

The multi-year refranchising campaign has removed low-margin, capital-intensive bottling from the parent’s balance sheet. In 2025, Coca-Cola HBC AG agreed to acquire 75% of Coca-Cola Beverages Africa in a transaction valuing the African bottler at $3.4 billion, with Coca-Cola divesting 41.52% of its 66.52% stake.

The Indian bottling operation is following the same playbook. In July 2025, the company sold a 40% stake in Hindustan Coca-Cola Holdings to a Jubilant Bhartia Group affiliate, continuing the shift toward local partner ownership across emerging markets.

The strategic logic is that concentrate economics compound at higher ROIC than owning trucks, warehouses, and PET blow molders. The proceeds flow into brand M&A and shareholder returns.

Subscribe now

Category-Winning Portfolio Diversification

Fairlife has quietly become the growth engine most casual observers still overlook. The premium ultra-filtered dairy brand passed $1 billion in sales some time ago and is described by the company as its fastest-growing US brand.

The category is entirely misaligned with the “less soda” narrative, precisely because Fairlife trades on protein and functional nutrition rather than indulgence. Coca-Cola announced a $650 million investment in the Coopersville, Michigan facility, with construction set to begin in 2026, adding roughly 150 jobs.

Zero Sugar continues its double-digit run. The company’s own commentary from Q4 2025 results referenced 14% growth in the Zero Sugar brand family, a signal that recipe innovation is defending share even as consumers cut back on classic full-sugar variants.

PORTFOLIO DIVERSIFICATION HIGHLIGHTS
- Fairlife: fastest-growing US brand for KO
- Coke Zero Sugar: sustained double-digit growth
- Fairlife capacity expansion: $650M in Michigan (2026)
- Category focus: protein, hydration, coffee, tea

Subscribe now

Weaknesses

Structural Exposure to Sugar Regulation and Reformulation Costs

Coca-Cola remains disproportionately exposed to global sugar taxes and reformulation mandates. The company already reformulates recipes country by country, absorbing complexity and cost that pure water or coffee competitors do not carry.

In July 2025, the company confirmed it will launch a US cane sugar version of Coke following public pressure, while continuing to defend high-fructose corn syrup as safe. This introduces manufacturing complexity, dual supply chains, and margin dilution risk in the near term.

Reformulation is not a one-time event. Each market’s evolving front-of-pack labeling rules, sugar levies, and health authority guidance compound into a permanent operating cost.

Heavy Reliance on the Bottling Ecosystem

The refranchising strength is also a dependency. The company’s brands only reach consumers through the execution quality of its bottling partners. Any local partner underperformance shows up in Coca-Cola’s volume figures with a lag.

Q1 2026 volume in the Asia Pacific segment was up 5%, but reported segment operating income fell 14%, a reminder that regional profitability can move against volume as bottler mix and currency shift. The company also flagged an approximate 4% headwind from acquisitions and divestitures for 2026 comparable revenues.

Investors reading a headline volume figure need to reconcile it against bottler contribution mix, especially as refranchising continues.

Subscribe now

Litigation and Reputational Exposure at Fairlife

Fairlife has been dragged through repeated animal welfare litigation, including a $21 million class-action settlementoriginally paid in 2022 tied to deceptive marketing claims. Additional suits continued into 2026.

While these amounts are financially immaterial to a company generating $12 billion in annual free cash flow, they threaten the premium positioning that justifies Fairlife’s shelf price. Value-added dairy brands live and die on trust in sourcing narratives.

The Fairlife contingent consideration payment materially impacted 2025 free cash flow, which was $5.3 billion reported versus $11.4 billion excluding the payment. Cash outflows from prior deal structures are still working through the P&L.

Currency Translation Headwinds

Because concentrates are priced and sold globally, Coca-Cola’s reported financials are highly sensitive to FX. Full-year 2026 guidance embeds a 1% to 2% currency tailwind for comparable net revenues, but this can flip quickly.

The Q1 2026 press release explicitly reconciles that guidance depends on current spot rates and hedging positions. FX volatility across Latin American and African currencies has produced double-digit swings in reported segment revenue during 2024 and 2025.

Subscribe now

Rolled-Back Sustainability Commitments

In December 2024, the company revised its voluntary environmental goals, extending timelines to 2035 and softening targets. Recycled content in primary packaging now aims for 35% to 40% by 2035, down from earlier ambitions closer to 50% by 2030.

The collection ambition is now 70% to 75% by 2035, and the World Wildlife Fund and other stakeholders publicly criticized the retreat. The change was documented in an Oceana report on plastic waste, which continues to place Coca-Cola near the top of global plastic footprint rankings.

This creates real ESG downgrade risk for institutional mandates that screen on plastic pollution.

KEY 2035 ENVIRONMENTAL GOALS (revised Dec 2024)
- Recycled material in primary packaging: 35%-40%
- Recycled plastic (rPET): 30%-35% globally
- Package collection rate: 70%-75%
- Emissions: 1.5C trajectory (excludes acquired brands)

Opportunities

Read more

Executive TL;DR

• ASML posted a record 2025 with €32.7 billion in total net sales and a 52.8% gross margin, followed by a €8.8 billion Q1 2026 quarter and a raised full-year 2026 revenue band of €36 billion to €40 billion.

• The company remains the sole global supplier of EUV lithography equipment, shipping 42 EUV systems in Q1 2026 alone, and it targets 60+ EUV shipments plus 10 High-NA scanners for the full year.

• Free cash flow reached €12.5 billion in 2025, and management authorized a fresh €12 billion buyback running through 2028 alongside a raised final dividend of €2.70 per share.

• A few key risks dominate the outlook: escalating US export restrictions that may compress the China share to 20% of sales, and the pace of High-NA adoption at TSMC, which has publicly hesitated on cost.

Recommended - Read Full Reports

Read All Reports

Introduction

Almost every high-performance chip in the world depends on a machine built in a small Dutch town called Veldhoven. That machine costs more than a wide-body jet, weighs more than two Airbus A320s, and no company on Earth other than ASML knows how to build one at scale.

For US investors, this is the strangest kind of business to underwrite: a European industrial with an effective monopoly on the single most important tool inside every $30,000 AI chip. It sits at the exact chokepoint where geopolitics, artificial intelligence capex, and physics collide.

The stock has whipsawed violently through 2025 and into 2026 as investors have tried to reconcile record bookings with US export policy volatility.

This report unpacks what the numbers actually say, what the technology roadmap really looks like, and where the risks live inside the story.

Subscribe now

ASML Company Profile: Key Facts

ASML Holding N.V. is a Dutch multinational headquartered in Veldhoven, Netherlands. It designs, manufactures, and services photolithography systems used by every leading-edge semiconductor manufacturer on the planet.

Its stock trades on Euronext Amsterdam under the ticker ASML and on Nasdaq under the same ticker as an ADR. The company follows a dual-listing structure and reports under both US GAAP and IFRS.

COMPANY SNAPSHOT — ASML HOLDING N.V.

Founded:              1984 (joint venture Philips / ASM International)
Headquarters:         Veldhoven, Netherlands
Chief Executive:      Christophe Fouquet
Employees:            ~44,000 (60+ locations, 16 countries)
Listings:             Euronext Amsterdam (ASML), Nasdaq (ASML)
FY 2025 net sales:    €32.7 billion
FY 2025 gross margin: 52.8%
FY 2025 R&D spend:    €4.7 billion
Systems shipped:      535 units (all types, 2025)
EUV market share:     100% (sole global supplier)
DUV market share:     ~90% (industry estimates)

The product portfolio spans three main categories: Extreme Ultraviolet (EUV) systems, Deep Ultraviolet (DUV) systems that include ArF immersion and dry KrF scanners, and metrology and inspection tools used to measure the wafers coming off those scanners.

Sitting alongside all of this is a fast-growing service and field-options business that generates recurring revenue over the multi-decade life of an installed base.

Subscribe now

The ASML Business Model

In simple terms, ASML sells extremely expensive chipmaking machines to a very small list of customers. In 2025, roughly 90% of system revenue came from a handful of manufacturers: TSMC, Samsung, SK Hynix, Micron, and Intel.

Each machine is more than a product. A single EUV scanner is a 180-ton, room-sized system with 100,000+ components, and once installed inside a fab, it runs 24/7 for years, generating a service annuity that ASML captures through parts, upgrades, and software.

The elegance of the business is that the “razor and the blades” are both proprietary. The company sells the machine for hundreds of millions, then earns a growing tail of upgrade revenue as chipmakers extend the useful life of tools to squeeze more nodes out of the same capital base.

Subscribe now

Financial Performance: 2025 Was a Record Year

The 2025 fiscal year delivered a set of numbers that even bullish analysts underestimated. Total net sales grew 15.6% to €32.7 billion, driven mostly by system sales but with meaningful contribution from installed base management.

Gross margin printed at 52.8%, R&D expense reached €4.7 billion, and basic earnings per share came in at €24.73. Net service and field-options sales exposed the recurring engine underneath the systems business, expanding as the installed base grew.

Cash generation was equally strong.

Operating cash flow hit €12.66 billion for the year, and free cash flow reached $12.5 billion for 2025, a 27% jump on the prior year.

FY 2025 FINANCIAL SUMMARY (US GAAP, EUR)

Total net sales:            €32.7B    (+15.6% YoY)
Net system sales:           ~€26.2B   (+12.4% YoY)
Net service & field options: €6.5B    (installed base driven)
Gross margin:                52.8%
R&D expense:                 €4.7B    (+9.2% YoY)
Basic EPS:                   €24.73
Operating cash flow:         €12.66B
Free cash flow (USD):        $12.5B   (+27.4% YoY)
Systems shipped (all):       535 units
EUV systems shipped:         Robust growth, memory demand rising

The number that mattered most to the market was net bookings. Q4 2025 alone printed €13.2 billion in bookings, roughly double consensus expectations, and pushed the backlog to €38.8 billion.

That backlog effectively locks in the front half of 2027 before management even guides to it.

It’s also the number that most cleanly demonstrates

Read more

Executive TL;DR

• Blue Origin closed its first-ever outside funding round at a $130 billion valuation on July 8, 2026, raising roughly $10 billion led by Coatue Management, marking a philosophical break from 26 years of pure Bezos self-funding.

• The company is recovering from a May 28, 2026 static-fire explosion that destroyed the NG-4 vehicle and heavily damaged Launch Complex 36, with CEO Dave Limp targeting a return to flight before the end of 2026.

• Government contract backlog is substantial: $2.4 billion NSSL Phase 3 Lane 2 with the Space Force plus a Human Landing System award for Artemis V and a fresh Moon Base I contract worth $230.4 million.

• Structural headwind: SpaceX’s operational cadence dwarfs Blue Origin’s, and Amazon’s Project Kuiper deployment deadlines are actively threatened by the current New Glenn stand-down.

Recommended - Read Full Reports

Read All Reports

Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.

Introduction

Blue Origin just did something Jeff Bezos said it would never need to do.

On July 8, 2026, the company confirmed a $10 billion capital raise, split between $2 billion from Bezos himself and roughly $8 billion from Coatue Management and other outside investors, valuing the rocket maker at $130 billion.

That headline number arrived exactly six weeks after a New Glenn rocket detonated on Launch Complex 36 during a routine engine test, gutting the pad that Blue Origin had spent nearly a decade rebuilding.

The timing of the raise, sitting between a very public failure and a promised return to flight, is the entire story for investors trying to underwrite the next chapter.

The premise of this analysis is simple. Blue Origin is a private company, but the checks it now writes and receives touch public capital allocators, defense budgets, NASA program schedules, and the launch cadence of Amazon’s satellite constellation.

What happens inside a Kent, Washington headquarters and a Huntsville engine floor matters for anyone allocating to space, defense, or Big Tech infrastructure.

This report walks through the corporate structure, the current product portfolio, contract backlog, capital structure, competitive positioning against SpaceX, the operational overhang from the NG-4 loss & more.

Let’s analyze everything in detail.

Subscribe now

Blue Origin Company Profile: Key Facts

Blue Origin LLC was founded in September 2000 by Jeff Bezos, initially operating from a warehouse in Seattle before consolidating at its now-familiar O’Neill Building headquarters in Kent, Washington.

For 25 years the enterprise was funded almost exclusively by Bezos personally, at a reported clip of about $1 billion per year in liquidated Amazon stock.

That posture ended now with the Coatue-led round.

COMPANY SNAPSHOT
Founded:          September 8, 2000
Founder:          Jeffrey P. Bezos
CEO:              Dave Limp (Dec 2023 – present)
Headquarters:     Kent, Washington
Employees:        ~12,600 (post-Feb 2025 layoffs)
Ownership:        Private (Bezos majority; Coatue-led minority as of Jul 2026)
Latest Valuation: $130 billion (Jul 8, 2026)
Motto:            Gradatim Ferociter

Dave Limp, the former head of Amazon Devices, replaced founding CEO Bob Smith in December 2023. His mandate has been to shift the culture from what critics called a slow, cost-plus contractor mindset toward a commercial cadence more comparable to SpaceX’s.

The company operates a distributed U.S. manufacturing footprint.

Rocket integration and headquarters are in Kent. Engine production sits in a 300,000-square-foot factory in Cummings Research Park, Huntsville, Alabama. Launch operations are centered at Cape Canaveral, with rocket testing at Corn Ranch in West Texas.

Workforce numbers deserve attention. Blue Origin peaked near 14,000 employees in early 2025, then announced a 10 percent workforce reduction in February 2025, bringing headcount to roughly 12,600 by the end of that year.

Limp framed the cuts as removing management layers to accelerate decision-making, not as a retreat from strategic ambition.

Subscribe now

The $130 Billion Funding Round: A Historic Pivot

The July 2026 capital raise deserves granular attention because it fundamentally changes the investor calculus around Blue Origin. This is the first outside equity the company has taken in 26 years of operation.

The round totals about $10 billion, with $4 billion coming from Coatue Management as the lead investor, $2 billion from Bezos personally, and the balance from other institutional investors. The pre-money valuation is $130 billion.

For context, that valuation puts Blue Origin at roughly one-third of SpaceX’s most recent secondary-market valuation and instantly makes it one of the highest-valued private companies in the United States.

FUNDING ROUND STRUCTURE (July 8, 2026)
Total raise:            ~$10 billion
Lead investor:          Coatue Management ($4B)
Bezos participation:    $2 billion
Other participants:     ~$4 billion (undisclosed institutional LPs)
Pre-money valuation:    $130 billion
Round type:             First outside capital in company history
Historical funding:     Prior ~$500M in publicly tracked rounds via Pitchbook

Why now? Two reasons converge.

First, the heavy-lift commercial market is capacity-constrained, and the Amazon Kuiper deployment obligation, national security launches, and the Blue Moon lunar program all demand parallel investment that exceeds even Bezos’s annual liquidation appetite.

Second, the shift signals Blue Origin is preparing to operate as a normal capital-markets participant. Ars Technica’s Eric Berger noted that Bezos wants to limit his own investments and provide funding for growth. That is the language of a company on a path to IPO, though management has offered no formal timeline.

For investors, the practical takeaway is that Blue Origin’s fundraising will now be visible, sequential, and increasingly benchmarked against operational milestones rather than founder patience.

Subscribe now

The New Glenn Program: State of Play After NG-4

New Glenn is the linchpin.

Everything else in the Blue Origin portfolio, from lunar landing to national security missions to Kuiper, depends on a reliable orbital rocket.

Understanding

Read more

Wall Street returns from the Independence Day weekend with the Dow at a fresh record close and the S&P 500 sitting a whisker below its own peak.

The tape looks calm on the surface, yet three catalysts are stacked into a single trading week: FOMC meeting minutes, the unofficial start of Q2 earnings season with PepsiCo and Delta, and a consumer credit data that could reprice risk overnight.

June’s payrolls surprise (57,000 jobs added versus the 115,000 consensus) has already shifted the rate debate.

Investors now want to know whether the new Fed chair sees enough weakness to soften the “higher for longer” stance, or whether sticky 4.2% CPI inflation keeps the pause in place.

Here’s what actually matters between Monday, July 6 and Friday, July 10, 2026, with the top considerations and positioning tips for this trading week.

Recommended - Read Full Reports

Read All Reports

Where the Market Stands Heading Into the Week

The Dow closed at a record high on July 2, gaining nearly 600 points on the session as soft labor data revived hopes that a hawkish Fed might have less room to lift rates further. The record close on July 2 capped a solid pre-holiday run.

The S&P 500 settled the week at 7,483.24, up 1.76% on the week per Dow Jones data. The Nasdaq finished lower for the session as chip stocks wobbled, but still logged weekly gains.

Pre-Week Snapshot (Close, July 2, 2026)
Dow Jones Industrial Average: Record closing high
S&P 500: 7,483.24 (+1.76% for the week)
Nasdaq Composite: Weekly gain, session decline
10-Year Treasury Yield: 4.48%
Gold: Above $4,130/oz
Fed Funds Target Range: 3.50%–3.75% (held in June)

Bond yields remain the elephant in the room.

The 10-year Treasury yield printed 4.48% on July 1, meaning cash and short-duration Treasuries still offer real competition to equities.

Gold’s move above $4,130 signals ongoing safe-haven demand. That’s worth watching alongside equity records, because it hints that a portion of the buy-side is hedging tail risk even as major indexes press higher.

Top 11 Highlights & Major Considerations for July 6–10, 2026

1. FOMC Minutes on Wednesday Are the Marquee Event

The June 16–17 FOMC meeting held the target range at 3.50–3.75% for the fourth straight time.

The minutes drop at 2 p.m. ET on Wednesday, July 8.

This will be the first set of minutes released under Chair Kevin Warsh’s tenure. Warsh has publicly downplayed the value of long-range forecasts and did not participate in the June dot plot, so investors will pore over language on inflation, tariffs, and labor market softness.

The June dot plot showed nine officials still expecting at least one hike before year-end.

Any hint that the committee is quietly moving away from that stance could rally rate-sensitive small caps and housing.

2. PepsiCo (PEP) Q2 Earnings on Thursday Morning

PepsiCo reports Q2 2026 results on Thursday, July 9 before the open, with the conference call at 8:15 a.m. ET. Consensus EPS is roughly $2.19–$2.21.

Several sell-side analysts trimmed price targets into the print, so the setup skews cautious.

Watch North American beverage volumes, Frito-Lay pricing power, and any hint about GLP-1 medication impact on snack demand.

3. Delta Air Lines (DAL) Officially Opens Airline Earnings

Delta’s Q2 2026 earnings webcast is scheduled for 10:00 a.m. ET on Friday, July 10. Management previously guided to a June-quarter pre-tax profit of roughly $1 billion.

Wall Street expects diluted EPS near $1.43–$1.44, a year-over-year decline as capacity-cost economics normalize. The March-quarter release noted record Q1 revenue of $14.2 billion and reaffirmed a full-year 2026 EPS range of $6.50 to $7.50.

Delta’s guidance is more valuable than the print.

As the summer bellwether, its commentary on premium cabin, corporate travel, and transatlantic bookings feeds directly into United, American, and Alaska Airlines.

Read more